RAYMOND K - University of Maryland, Baltimore
CURRICULUM VITAE
Raymond K. Cross, Jr., M.D., M.S.
Professor of Medicine, Department of Medicine
Division of Gastroenterology and Hepatology
University of Maryland School of Medicine
Date May 27, 2020
CONTACT INFORMATION
100 North Greene Street, Lower Level
Baltimore, MD 21201
Office: (410) 706-3387
Fax: (410) 706-4330
E-mail: rcross@medicine.umaryland.edu
EDUCATION
1989-1993 B. A., Biology (Summa cum laude)
Washington and Jefferson College
Washington, PA 15301
1993-1997 M.D.
University of Pittsburgh School of Medicine
Pittsburgh, PA 15260
2003-2006 M.S., Clinical Research
University of Maryland, Baltimore
POST GRADUATE EDUCATION AND TRAINING
1997-2000 Internal Medicine Residency Training
University of Maryland and Baltimore VA Medical Centers
2000-2001 Chief Medical Resident
University of Maryland and Baltimore VA Medical Centers
2001-2004 Gastroenterology Fellowship Training
University of Maryland and Baltimore VA Medical Centers
CERTIFICATION
2000-2010 Diplomate, American Board of Internal Medicine
2004-2024 Diplomate, American Board of Internal Medicine - Gastroenterology
MEDICAL LICENSURES
2000 State of Maryland (active)
EMPLOYMENT HISTORY
Academic Appointments
1999-2000 Assistant Instructor, Department of Medicine
University of Maryland School of Medicine
2000-2004 Clinical Instructor, Department of Medicine
University of Maryland School of Medicine
2004-2009 Assistant Professor, Department of Medicine
University of Maryland School of Medicine
2006-present Faculty Associate
University of Maryland School of Nursing
2009-2016 Associate Professor, Department of Medicine
University of Maryland School of Medicine
2016-present Professor, Department of Medicine
University of Maryland School of Medicine
Other Employment
1994 Research Assistant, Department of Pharmacology
Said Sebti, Ph.D. (Mentor)
University of Pittsburgh School of Medicine, Pittsburgh, PA
2000-2004 Consultant, Urgent Care Service
VA Maryland Health Care System, Baltimore
2001-2004 Consultant, Managed Care Service
VA Maryland Health Care System, Baltimore
PROFESSIONAL SOCIETY MEMBERSHIPS
2001-present American College of Gastroenterology, Member
2001-2004 American Society of Gastrointestinal Endoscopy
2001-present American Gastroenterological Association, Member
2003-present Crohn’s and Colitis Foundation of America, Member
2017-present American Telemedicine Association, Member
HONORS AND AWARDS
1990-1992 Division III Academic All-American in Football
1991 Phi Sigma Biology Honorary Society
1993 Birch Student Athlete Award, Washington and Jefferson College
1993 Phi Beta Kappa, Washington and Jefferson College
1993 NCAA Post-Graduate Scholar
1996 Alpha Omega Alpha, University of Pittsburgh School of Medicine
1997 Leo H. Kriep Award for Medicine, University of Pittsburgh School of Medicine
2005-2006 Teaching Commendation, Pathophysiology & Therapeutics II, Gastroenterology-Hematopathology Unit
2007 Best Practices, Colorectal Cancer Collaborative, VA Maryland Health Care System
2007-2009 Recipient, NIH Clinical Loan Repayment Program
2007-2008 Certificate of Teaching Excellence, Functional Systems Small Group Conferences
2010 American College of Gastroenterology IBD Abstract Award Recipient
2011 Crohn’s and Colitis Foundation, Maryland and Southern Delaware Chapter, Chairman’s Citation Award
2011-2013 Washington DC-Baltimore-Northern Virginia Super Doctors
2012 American Gastroenterological Association Fellow
2012 American College of Gastroenterology Presidential Poster Recipient
2013-2014 Teacher of the Year, Division of Gastroenterology and Hepatology, University of Maryland, Baltimore
2016 Healio Gastroenterology 200 Innovators in Gastroenterology and Hepatology
2017 American College of Gastroenterology Presidential Poster Recipient
2018 Fellow, American College of Gastroenterology
2018-2019 Baltimore Magazine, Top Doctor, Gastoenterology: Inflammatory Bowel Disease
2018 Outstanding Faculty Mentor Award, Department of Medicine, University of Maryland, Baltimore
2019 Excellence in Healthcare Award, Crohn’s and Colitis Foundation, Maryland/Southern Delaware Chapter
Clinical Activities
Clinical Expertise
o Evaluation and treatment of patient with inflammatory bowel diseases, infectious colitis, celiac disease, and chronic diarrhea
o Application of advanced dysplasia/cancer screening techniques in patients with inflammatory bowel disease
o Endoscopic balloon dilation in patients with intestinal strictures
o Management of intravenous therapeutics in patients with inflammatory bowel disease
o Management of patients with short bowel syndrome
Scope of Clinical Practice
Site of Primary Practice and size:
• The Inflammatory Bowel Disease Program was developed in July 2004
• Multidisciplinary hospital outpatient clinic within the Digestive Health Center of the University of Maryland Medical Center
• The program has over 1,700 patients with inflammatory bowel disease
• The Infusion Program was developed in 2005 to provide intravenous therapeutics to patients with inflammatory bowel disease, rheumatoid arthritis, psoriasis, and other inflammatory disorders
Time Spent in Clinical Duties and Responsibilities:
• Total time spent in clinical duties includes 2 extended half days of clinic per week and one day of endoscopy per week.
• The program provides inpatient care for all private and complicated inflammatory bowel disease patients
• Director of the Inflammatory Bowel Disease program
Innovative Techniques
o Multidisciplinary clinic:
• Designed to combine the expertise of gastroenterologists, surgeons, dieticians, and infusion services
o Magnification chromoendoscopy:
• The inflammatory bowel disease program currently performs this technique in all patients with chronic colitis undergoing surveillance colonoscopy for cancer prevention
o Endoscopic balloon dilation:
• The inflammatory bowel disease program has expertise in balloon dilation of intestinal strictures in patients with Crohn’s disease and intestinal ischemia (see Abstracts and/or Proceedings below)
o Telemedicine:
• The inflammatory bowel disease program has developed a telemedicine system for research (see AHRQ funded study below) and telehealth visits for clinical purposes to monitor, evaluate, and treat patients in the outpatient setting
Administrative Service
Institutional Service
2000-2001 Ambulatory Education Committee
Department of Medicine, University of Maryland School of Medicine
2000-2001 Medical Student Education Committees
University of Maryland School of Medicine
2000-2001 Postgraduate Education Committee
Department of Medicine, University of Maryland School of Medicine
2000-2001 Resident Selection Committee
Department of Medicine, University of Maryland School of Medicine
2004-present Director, Inflammatory Bowel Disease Program
University of Maryland Medical Center
2007. Chief, Inflammatory Bowel Disease Section
Medicine Service, Gastroenterology Section
Veterans Affairs, Maryland Health Care System, Baltimore
2004-2011 Chairman, Equipment Committee
Veterans Affairs, Maryland Health Care System, Baltimore
2005-2011 Chief, Gastroenterology Section, Medicine Service
Veterans Affairs, Maryland Health Care System, Baltimore
2005-2007 Member, Dissertation Committee, PhD Candidate Meaghan Donovan
University of Maryland School of Pharmacy
2005. Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
2006. Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
2007. Co-Director, Inflammatory Bowel Disease and Irritable Bowel Syndrome Symposium University of Maryland School of Medicine
2008-2010 Medical Student Education Committee
University of Maryland School of Medicine
2008-2009 Ad hoc member, Medical Executive Committee
University of Maryland Medical System
2010. Member-Elect, University of Maryland School of Medicine Council
University of Maryland School of Medicine
2008-2010 Member, Dissertation Committee, PhD Candidate Alejandra Faust
2009 Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
2010 Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
2011-present Co-Director, Digestive Health Center
University of Maryland Medical Center
2011 Enterprise Risk Management Initiative
Member, Subject Area Workgroup focused on Research University of Maryland
2011-2012 Compliance Director. Division of Gastroenterology and Hepatology, Department of Medicine University of Maryland Medical Center
2012 Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
2012-present Telehealth Executive Committee
University of Maryland Medical System
2013-present Co-Program Director
Leader of the Clinical and Translational Science Track
NIH/NIDDK Research Training in Gastroenterology
2014 Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
2017 Co-Director, Inflammatory Bowel Disease Symposium
University of Maryland School of Medicine
Local Service
2004-present Member, Physician Advisory Board
Crohn’s and Colitis Foundation of America, Maryland/Delaware Chapter
2007-2012 Chair, Mission Committee
Crohn’s and Colitis Foundation of America, Maryland/Delaware Chapter
2010-2012 Board of Directors, Crohn’s and Colitis Foundation of America, Maryland/Delaware Chapter
National Service
2008-present Ad Hoc Reviewer, Broad Medical Research Program
2008-present Member, Clinical Research Alliance, Crohn’s and Colitis Foundation of America
2008-2011 Member, Crohn’s and Colitis Foundation of America National Patient Education Committee
2009-2016 Section Editor, Clinical Section, Inflammatory Bowel Diseases
2011 Member, Editorial Board, Gastrointestinal & Digestive System
2011-2015 Member, Clinical Review Committee, Crohn’s and Colitis Foundation of America
2011 Member, Review Panel, Department of Defense Peer Reviewed Medical Research Program (PRMRP)
2011-present Member, Review Panel, Clinical Research Alliance Pilot Grants, Crohn’s and Colitis Foundation of America
2011-2015 Chair, Crohn’s and Colitis Foundation of America National Patient Education Committee
2012-2014 Member, Crohn’s and Colitis Foundation of America Partners Executive Committee
2012-present Member, IBD Advisory Board, Gi Health Foundation
2013 Member, Review Panel, Autoimmune Centers of Excellence, Clinical and Basic Research Program, National Institute of Allergy and Infectious Disease
2013-2017 Member, Review Panel, IBD: Uncontrolled Therapeutic Observations in Humans, AGA Institute Council
2014-2016 Chair, Review Panel, IBD: Quality of Life/Psychosocial Care, AGA Institute Council
2014 Member, Review Panel, IBD Abstracts, American College of Gastroenterology
2014-2017 Member, Crohn’s and Colitis Foundation of America Partners Project Selection Committee
2015 Chair, IBD Abstract Review Committee, American College of Gastroenterology
2015-2018 Chair, Crohn’s and Colitis Foundation National Clinical Research Grants Review Committee
2015-present Member, Crohn’s and Colitis Foundation Senior Research Advisory Council
2016 Member, Clinical Organizing Committee, 2016 Advances in Inflammatory Bowel Diseases, Crohn’s and Colitis Foundation’s Clinical and Research Conference
2018 Chair, Review Panel, IBD: Practice Management/Quality of Care/Quality Assurance, AGA Institute Council
2016-2021 Associate Editor, Inflammatory Bowel Diseases
2019-present Co-Director, Corrona IBD Registry
2019-present Member, Global Interventional Inflammatory Bowel Disease Group
Journal Reviews
2006-present Ad Hoc Reviewer, Inflammatory Bowel Diseases (6x/year)
2007-present Ad Hoc Reviewer, American Journal of Gastroenterology (4x/year)
2007-present Ad Hoc Reviewer, Gastroenterology (4x/year)
2007-present Ad Hoc Reviewer, Journal of Clinical Gastroenterology (0-1x/year)
2009-present Ad Hoc Reviewer, Gastrointestinal Cancer Research (0-1x/year)
2010-present Ad Hoc Reviewer, Digestive Disease Sciences (2x/year)
2010-present Ad Hoc Reviewer, Clinical and Experimental Gastroenterology (0-1x/year)
2011-present Ad Hoc Reviewer, Journal of Pediatrics (0-1x/year)
2011-present Ad Hoc Reviewer, Gastroenterology and Hepatology (0-1x/year)
2012-present Ad Hoc Reviewer, Clinical Gastroenterology and Hepatology (4x/year)
2014 Ad Hoc Reviewer, European Journal of Gastroenterology and Hepatology (0-1x/year)
Teaching Service
Student Teaching
2000-2003 Small group instructor (4 students, 3 hours/week)
Introduction to Clinical Medicine, Course II (ICME 520)
2002-present Small group instructor (16-18 students, 4 hours/year)
Gastroenterology physiology
Functional Systems Course (MSPR 515)
2002-present Small group instructor (16-18 students, 5-10 hours/year)
Pathophysiology and Therapeutics II (MSPR 521)
2004-2012 Small group instructor (15 students, 2 hours/year)
Medicine Clerkship (MEDC 530)
2005-2014 Lecturer (~160 students, 1 hour/year)
Disorders of the Large Intestine
Pathophysiology and Therapeutics II (MSPR 521)
2005-2007 Lecturer (~35 students, 1 hour/year)
Overview of Inflammatory Bowel Disease
Adult Nurse Practitioner Program (Nurs 647)
Resident/Fellow Teaching
2000-2001 Attending Physician In-patient Service
1 resident, 2 interns, 2 3rd year medical students
8 hours/day, 2 months/year
2000-2001 Attending Physician Outpatient Clinic
10 interns/residents
5 hours/day, 1 day/ week, 6 months per year
2004-present Attending Physician Outpatient Gastroenterology Clinic
3-4 residents/fellows, 0-1 students
4 hours/day, 1 day/week, 6 weeks per year
2004-present Attending Physician Inpatient Gastroenterology Consult Service
3-5 residents/fellows, 1-2 students
6-8 hours per day, 5 days/week, 2 weeks per year
2004-present Attending Physician Outpatient Inflammatory Bowel Disease Clinic
1-2 residents/fellows, 0-1 students
6-7 hours per day, 2 days per week
2004-present Attending Physician Inpatient Inflammatory Bowel Disease Consult Service
1-2 residents/fellows, 0-1 students
2-3 hours per day, 5 days per week, 8 weeks per year
2004-present Lecturer
Overview of Inflammatory Bowel Disease and Treatment of Inflammatory Bowel Disease
20 residents, 10 students
2 hours per year
2012-present Lecturer
Research Skills 101
~10-15 residents
1 hour per year
2014 Lecturer
Overview of Inflammatory Bowel Disease and Treatment of Inflammatory Bowel Disease
Surgery Residents Curriculum Series
~20 residents
1 hour
Mentoring Activities
2002-2005 Amy Schuster, 2nd year medical student
2004, 2010 Grishma Joshi/Joy, 2nd year medical resident-gastroenterology fellow
2004. Sharmeel Wasan, 2nd year medical resident
2005 Priti Bijpuria, 2nd year medical resident
2005-2015 Mark Flasar, gastroenterology fellow-faculty
2005-present Sandra Quezada, 4th year medical student-resident-academic fellow
2005-2008 Meaghan St. Charles. Ph.D. candidate, School of Pharmacy.
2006 Roger Wu, 4th year medical student
2007 Rachel Greenberg, Intern
2007 Dafna Koldobskly, Intern
2007 Roxana Samimi, 4th year medical student
2008-2009 Roderick Kreisberg, gastroenterology fellow
2007-2016 Leyla Ghazi, gastroenterology fellow
2008-2010 Alejandra Faust, Ph.D. candidate University of Albany, SUNY
2008-present Seema Patil, M.D., gastroenterology fellow
2008 Amer Skopic, gastroenterology fellow, National Capital Consortium
2008 Ganesh Veerappan, gastroenterology fellow, National Capital Consortium
2009 Jordan Wolff, gastroenterology fellow
2010 Angelica Belo, gastroenterology fellow
2010 Kim Wyatt, gastroenterology fellow, National Capital Consortium
2010-2013 Member, Advisory Committee, Eric Goldberg, M.D.
2010-2015 Member, Advisory Committee, Mark Flasar, M.D., M.S.
2010-2016 Member, Advisory Committee, Leyla Ghazi, M.D.
2011-2016 Member, Advisory Committee, Darryn Potosky, M.D.
2010-2013 Sanam Razeghi, intern
2010-2011 John Betteridge, gastroenterology fellow, National Capital Consortium
2010-2011 Josh Watson, gastroenterology fellow, National Capital Consortium
2010-2011 Aparna Kishor, medical student
2010-2013 Winnie Szeto, 2nd year medical resident
2011-present Samantha Zullow, medical student
2011 Danielle Oliver, undergraduate student
2012 Julie McClellan, undergraduate student
2012-present Member, Advisory Committee, Seema Patil
2012-present Member, Advisory Committee, Lance Uradomo, MD, MPH
2012-2014 Matilda Hagan, gastroenterology fellow
2012 Mazer Ally, gastroenterology fellow, National Capital Consortium
2012 Adam Deising, gastroenterology fellow, National Capital Consortium
2012 Steven Armbruster, gastroenterology fellow, National Capital Consortium
2012-2016 Leon McLean, gastroenterology fellow
2013-present Member, Advisory Committee, Sandra Quezada, M.D., M.S.
2013 Tyler Watson, undergraduate student
2013 Frank Cheng, gastroenterology fellow, National Capital Consortium
2013 Rashad Wilkerson, gastroenterology fellow, National Capital Consortium
2014-present Sara Brown, 4th year medical student
2014-2016 Earl Cambell, 2nd year medical resident
2014-2017 Ali Syed, 4th year medical student
2014 Akash Gadani, 2nd year medical resident
2014 Mahoussi Aholoukpe, 1st year medical student
2014-2017 Joy Lee, 1st year medical student
2014-present Kaci Christian, 2nd year medical resident
2014-2016 Thomas Robertson, 4th year medical student
2014-2016 Member, Advisory Committee, Leon McLean, MD, MPH, PhD
2015-present Jamie Rosenstein, undergraduate student
2016-present Uni Wong, gastroenterology fellow/faculty
2016-present Kene Chudy-Onwugaje, gastroenterology fellow
2016-2017 Alexander Mamunes, medical student
2017-present Ameer Abutaleb, gastroenterology fellow
2017-present Nauroz Syed, medical resident
2017-present Rajiv Perinbasekar, medical resident
2017-present Arsheya Patel, medical student
2017-present Sonia Abichandani, medical resident
2017-present Member, Advisory Committee, Uni Wong, MD
2018 Zaid Bilgrami, medical student
2018-present Matthew Schliep, medical student
2018-present Katherine Gheysens, medical resident
2018-present Lauren George, Advanced IBD Fellow
2018-present Scott Manski, medical resident
2018-present Harris Feldman, medical student
2019-present Erin Causey, medical student
2019-present Benjamin Twery, medical student
2019-present Mazen Tolaymat, academic fellow
Grant Support
Active Federal Grants
7/1/10-6/30/20 (Co-Investigator, 0%)
“NIH/NIDDK Research Training in Gastroenterology”
NIDDK T32 DK067872
Annual Direct Costs:
Total Direct Costs:
Training grant faculty, Member of Steering Committee, Co- Director of the Clinical & Translational Research Track
8/1/13-7/31/16 (no cost extension until 7/31/17) (Site-PI)
“Crohn’s Shared Decision Making Program Source”
Agency for Healthcare Research and Quality R01HS021747
Annual Direct Costs:
Total Direct Costs: $4,365
Active Foundation Grants
12/31/16- 12/31/17 (PI, 13%)
“Development of an Enhanced Telemedicine System to Improve Engagement and Adherence to Telemedicine for Patients with Inflammatory Bowel Disease.”
Crohn’s and Colitis Foundation of America
Annual Direct Costs: $115,451
Total Indirect Costs: $15,008
11/2/16- 12/31/18 (Site-PI, 10%)
“Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC-IBD).”
Crohn’s and Colitis Foundation of America
Annual Direct Costs: $110,000
Total Direct Costs: $11,000
7/1/15-12/31/16 (no cost extension requested until 12/31/17) (PI, 0%)
“Impact of Medical Treatment on Sexual Function in Patients with Crohn’s Disease”
American College of Gastroenterology Clinical Research Award (ACG-CR-007-2015)
Annual Direct Costs: $34,600.54
Total Direct Costs: $34,600.54
Active Industry Grants
8/1/17- 7/1/18 University of Maryland GI IBD Grand Rounds
Janssen Biotech
Total Direct: $43,322.00
1/1/17- 12/31/17 (PI, 5%)
“Characteristics associated with excess health care utilization in patients with inflammatory bowel disease.”
AbbVie
Total Direct: $ 102,819.34
6/11/13-7/31/15 (no cost extension until 7/31/17) (PI)
“Sexual Function in Patients with Crohn’s Disease”
AbbVie
Total Direct Costs: $58,192
RESEARCH SUPPORT
(Site-Principal Investigator)
“A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis.”
Receptos, Inc/ Celgene
Total Direct Costs: $66,367
(Site-Principal Investigator)
“A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis.”
Receptos, Inc/ Celgene Corporation
Total Direct Costs: $125,335
(Site- Principal Investigator)
“Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease.”
Gilead
Direct Costs: $150,420.00
(Site-Principal Investigator)
“A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease.”
Gilead
Direct Costs: $105,953.00
(Site- Principal Investigator)
“A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.”
AbbVie
Total Direct Costs: $299,406.50
(Site- Principal Investigator)
“A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and efficacy of ABT 494.”
Abbvie
Total Direct Costs: $390,603.50
Completed Research Support
2004 (PI)
“Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists in Maryland and Washington D.C”
Centocor, Inc.
Annual Direct Costs: $2,500
Total Direct Costs: $2,500
7/1/04-7/1/05 (PI)
“Home Telemanagement in Inflammatory Bowel Disease (IBD)”
University of Maryland School of Medicine Intramural Award Annual Direct Costs: $20,000
Total Direct Costs: $20,000
7/1/05-6/30/07 (PI)
“Educational Grant for Specialized Fellowship in IBD”
Centocor, Inc.
Total Direct Costs: $10,000
8/1/06-7/1/07 (PI)
“The Home Telemanagement Trial (UC HAT) in Patients with Ulcerative Colitis”
Baltimore Research and Education Foundation Grant
Total Direct Costs: $10,000
7/1/08-6/30/09 (PI)
“Educational Grant for Specialized Fellowship in IBD” Centocor, Inc.
Annual Direct Costs: $10,000
Total Direct Costs: $10,000
6/1/06-6/30/10 (PI)
“The Home Telemanagement Trial (UC HAT) in Patients with Ulcerative Colitis”
Eli & Edyth L. Broad Foundation IBD0190
Total Direct Costs: $238,836
7/1/08-6/30/10 (PI)
“Educational Grant for Specialized Fellowship in IBD”
Abbott Laboratories, Inc.
Total Direct Costs: $46,000
12/1/09-2/28/11 (Site-PI)
“Ulcerative Colitis PRO Development Protocol”
University of Michigan Medical School
Annual Direct Costs:
Total Direct Costs: $18,333
12/1/09-2/28/11 (Site-PI)
“Crohn’s Disease PRO Development Protocol”
University of Michigan Medical School
Annual Direct Costs:
Total Direct Costs:
8/27/10-8/26/11 (PI)
“What is the disease course after immune suppressant or biologic drug use in patients with Crohn’s disease?”
Abbott Laboratories
Annual Direct Costs: $72,595
Total Direct Costs: $72,595
9/4/09-9/3/11 (PI)
“The Impact of Inflammatory Bowel Disease and Aging on Body Composition and Functional Performance Source”
University of Maryland Claude D. Pepper Older Americans Independence Center
Annual Direct Costs:
Total Direct Costs: $30,000
3/1/08-8/31/12 (Site PI)
“Test-Treat Strategy to Prevent Ulcerative Colitis Relapse Dose Escalation and Remission (DEAR) Study”
NIDDK K24-DK078228
Annual Direct Costs:
Total Direct Costs: $14,297
5/14/09-5/13/12 (Site PI)
“A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis”
Millennium Pharmaceuticals, Inc.
Annual Direct Costs:
Total Direct Costs: $83,812
9/02/10-11/30/12 (Site-PI)
“A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Crohn’s Disease”
Millennium Pharmaceuticals, Inc.
Annual Direct Costs:
Total Direct Costs: $19,746
9/1/10-9/1/2012 (Co-investigator)
“Mechanism of Response to Anti-TNF Therapy in Inflammatory Bowel Disease”
Food and Drug Administration/National Institute of Health
Annual Direct Costs:
Total Direct Costs: $32,199
7/1/10-9/30/12 (PI)
“Risk factors for Progression of Crohn's Disease from Luminal to Complicated Disease: A Prospective Cohort Study”
Abbott Laboratories
Annual Direct Costs:
Total Direct Costs:
11/10/09 (no cost extension until 12/31/12) (PI)
“Differential Response to Microbial Antigens in Older Onset IBD” Prometheus Therapeutics & Diagnostics
Annual Direct Costs: None
Total Direct Costs: None
3/1/11-2/28/15 (Site-PI)
“Gene Discoveries in Subjects with Crohn's Disease of African Descent”
NIDDK 1R01DK087694-01A1
Total Direct Costs: $42,373
3/15/09-5/11/15 (Site-PI)
“INFORM: Investigating Natalizumab through Further Observational Research and Monitoring”
Elan Pharmaceuticals, Inc.
Total Direct Costs: $34,277
7/1/14-6/30/15 (PI)
“Advanced Fellowship in Inflammatory Bowel Disease”
AbbVie
Annual Direct Costs: $40,000
Total Direct Costs: $40,000
7/1/11-6/30/16 (Site Co-Inv, %)
“CTRC-Randomized Double Blind Prospective Trial Investigating the Efficacy of Methotrexate in Induction and Maintenance of Steroid-Free Remission in Ulcerative Colitis”
NIDDK 1U01-DK092239
Annual Direct Costs:
Total Direct Costs:
9/30/12-7/31/16 (PI, 15%)
“TELEmedicine in Patients with Inflammatory Bowel Disease: TELE-IBD”
Agency for Healthcare Research and Quality 1R01HS018975-01A1
Annual Direct Costs:
Total Direct Costs: $1,028,823
4/1/15-1/1/18 (Site-PI,)
“A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris suis Ova Treatment in Left-sided Ulcerative Colitis and its Effects on Mucosal Immune State and Microbiota”
Division of Allergy, Immunology, and Transplantation
National Institute of Allergy and Infectious Disease
Annual Direct Costs:
Total Direct Costs: $138,922
3/1/13-6/30/16 (Site-PI,)
“Does Mucosal Healing Matter for Clinically Quiescent Ulcerative Colitis”
Crohn’s and Colitis Foundation of America 287390
Annual Direct Costs:
Total Direct Costs: $8,400
6/26/09-6/25/15 (Site-PI,)
“A Phase 3, Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn’s Disease”
Millennium Pharmaceuticals, Inc.
Annual Direct Costs:
Total Direct Costs: $43,966
6/1/11-5/31/14 (Site-PI,)
“611: A Multicenter, open-label study to evaluate the safety of PROCHYMAL® (remestemcel-L) intravenous infusion in subjects who have received previous remestemcel-L induction treatment for treatment-refractory moderate-to-severe Crohn’s disease”
Osiris Therapeutics
Total Direct Costs: $7,749
6/1/11-5/31/15 (Site-PI,)
“603: A Phase III, multicenter, placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of PROCHYMAL® (ex vivo cultured adult human mesenchymal stem cells)) intravenous infusion for the induction of remission in subjects experiencing treatment-refractory moderate-to-severe Crohn’s disease”
Osiris Therapeutics
Annual Direct Costs:
Total Direct Costs: $33,612
12/31/14-12/31/17 (no-cost extension until 12/31/16) (Site-PI)
“Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort (“APRIL” Cohort)”
Crohn’s and Colitis Foundation of America
Annual Direct Costs: $12,100
Total Direct Costs: $1,200
7/1/15-6/30/16 (PI, 0%)
“Advanced Fellowship in Inflammatory Bowel Disease” Janssen
Annual Direct Costs: $40,000
Total Direct Costs: $40,000
11/17/15-8/31/18 (Site-Principal Investigator)
“A Phase III Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn’s Disease”
RedHill Biopharma Ltd.
Total Direct Costs: $65,901
6/1/2016-8/31/2021 (Site-Principal Investigator)
“A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Investigate The Efficacy and Safety of Mongersen (GED-0301) For The Treatment Of Subjects With Active Crohn’s Disease”.
Celgene Corporation
Total Direct Costs: $73,307
8/30/2016-4/31/2020 (Site- Principal Investigator)
“A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn's Disease.”
Celgene Corporation
Direct Costs: $97,404.20
5/17/2016-5/16/2018 (Site- Principal Investigator)
“Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease.”
Gilead
Direct Cost: $106,541
7/05/2017-7/04/2022 (Site- Principal Investigator)
“A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease
The goals of this project are to evaluate the long term safety of filgotinib in subjects with Crohn’s disease.”
Gilead
Direct cost: $89,852
4/29/2017-05/16/2021 (Site- Principal Investigator)
“A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.”
Abbvie
Direct cost $75,711
5/09/2017-5/08/2018 (Site- Principal Investigator)
“A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and efficacy of ABT 494.”
Abbvie
Direct cost $185,049
PUBLICATIONS
Peer-Reviewed Articles
1. Cross, RK, Longhitano, JP, Rapoport, AP, Cadogan, MA, Brown, LA and Mackowiak, PA. A 78-year-old man with pancytopenia and abnormal lymphocytes. The American Journal of Medical Sciences 2001;322:151-155.
2. Cross, RK, Longhitano, JP, Oursler, KA, Saladino, AJ, and Mackowiak, PA. A 75-year-old man with right upper quadrant pain and gallstones. The American Journal of Medical Sciences 2002;323:146-150.
3. Cross RK, Jr. and Howell, C. Two cases of spontaneous epidural abscess in patients with cirrhosis. South Med J. 2003;96:291-293.
Gobert, AP, Cheng, Y., Akhtar, M., Mersey, BD, Blumberg, DR, Cross, RK, Chaturvedi, R., Drachenberg, CB, Boucher, JL, Hacker, A., Casero, RA, Jr., and Wilson, KT. Protective role of arginase in a mouse model of colitis. J Immunol 2004;173:2109-17.
4. Cross RK, Wilson, KT, and Binion, DG. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005;21:1211-6
5. Cross RK, Wilson, KT, and Binion, DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol 2005;100(10):2225-9.
6. Cross RK and Binion, DG. “Narcotic use in patients with Crohn’s disease: reply form Drs. Cross and Binion.” Am J Gastroenterol 2006;101(6):1397-8.
7. Cross RK, Arora, M, and Finkelstein, J. Acceptance of telemanagement is high in patients with inflammatory bowel disease. J Clin Gastroenterol 2006;40(3):200-8.
8. Cross RK, Jung, C, Wasan, S, Joshi, G, Sawyer, R, and Roghmann, MC. Racial Differences in Disease Phenotypes in Patients With Crohn's Disease. Inflamm Bowel Dis 2006;12(3):192-198.
9. Castro, HK, Cross, RK, and Finkelstein, J. Using a Home Automated Telemanagement System (HAT): Experiences and Perceptions in Patients with Inflammatory Bowel Disease. AMIA Annu Symp Proc 2006;872.
10. Cross, RK and Finkelstein, J. Feasibility and Acceptance of a Home Telemanagement System in Patients with Inflammatory Bowel Disease: A 6-Month Pilot Study. Dig Dis Sci 2007;52(2):357-364.
11. Donovan, M, Lunney, K, Carter-Pokras, O, and Cross, RK. Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists. Dig Dis Sci. Aug 2007;52(8):1798-1805.
12. Dunnigan, M, Yfantis, H, Rapoport, AP, Hosseinzadeh, K, Gocke, CD, and Cross, RK. Large cell lymphoma presenting as a flare of colitis in a patient with common variable immune deficiency. Dig Dis Sci. 2007;52(3):830-4.
13. Cross, RK, Lapshin, O, and Finkelstein, J. Patient Subjective Assessment of Drug Side Effects in Inflammatory Bowel Disease. J Clin Gastroenterol. 2008;42(3):244-51
14. Flasar, MH, Johnson, T, Roghmann, MC, and Cross, RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study. Inflamm Bowel Dis. 2008;14(1):13-9
15. Flasar, M, Quezada, S, Bijpuria, P, Wu, Roger, and Cross, RK. Racial Differences in Extent, Severity, and Extraintestinal Manifestations in Patients with Ulcerative Colitis: A Retrospective Cohort Study. Dig Dis Sci. 2008;53(10):2754-2760
16. Greenberg, R, Greenwald, B, Ioffe, O, Roth, S, and Cross, RK. Squamous Dysplasia of the Rectum in a Patient with Ulcerative Colitis Treated with 6-Mercaptopurine. Dig Dis Sci. 2008;53(3):760-4.
17. Flasar, M, Roghmann, MC, and Cross, RK. “Disparities in IBD Care: Time to Correct a Problem: reply from Drs. Flasar, Roghmann, and Cross.” Gastroenterology. 2008;134(5):1618-1619.
18. Cross, RK. Another Anti-TNF Therapy for Patients with Crohn’s Disease (Summary of Schreiber, S, Khaliq-Kareemi, M, Lawrance, IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s Disease. N Eng J Med.
2007;357:239-250). Inflamm Bowel Dis. 2008;14(3):425-427.
19. Warren, JW, Howard, FM, Cross, RK, Good, J, Weissman, M, Wesselmann, U, Langenberg, P, Greenberg, P, and Clauw, D. “Antecedent non-bladder syndromes in a case control study of interstitial cystitis/painful bladder syndrome”. Urology. 2009;73(1):52-7.
20. Quezada, S, Turner, P, Alexiev, B, Daly, B, and Cross, RK. “Severe Refractory Orofacial Crohn’s Disease: Report of a Case”. Dig Dis Sci 2009;54(10):2290-5.
21. Cross, RK, Cheevers, N, and Finkelstein, J. Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). Dig Dis Sci 2009;54(11):2463-2472.
22. St. Charles, M, Weiss Smith, SR, Beardsley, R, Fedder, DO, Carter-Pokras, O, and Cross, RK. Gastroenterologists Prescribing of Infliximab: A National Survey. Inflamm Bowel Dis. 2009;15(10)1467-75.
23. Cross R and Finkelstein, J. Challenges in the design of a Home Telemanagement Trial for patients with ulcerative colitis. Clin Trials 2009;6(6)649-57.
24. Ghazi, L and Cross, RK. Fever of Unknown Origin in an Immune Suppressed Patient with Crohn’s Disease: An Unusual Cause. Practical Gastroenterology 2010;34(11):42-46.
25. Samimi, R, Flasar, MH, Kavic, S, Tracy, K, and Cross, RK. Outcome of Medical Treatment of Stricturing and Penetrating Crohn’s Disease: A Retrospective Study. Inflamm Bowel Dis. 2010;16(7):1187-1194.
26. Cross, RK, Cheevers, N, Rustgi, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). Inflamm Bowel Dis 2012;18(6):1018-1025.
27. Cross, RK. Application of Telemedicine for Inflammatory Bowel Disease: Review of the Literature and Future Implications. J Gastrointest Digest Sys. October 2011;1(e102).
28. Flasar, MH, Cross, RK, and Doman, DB. Current and Future Role of Ulcerative Colitis Serogenomics. Gastroenterology and Hepatology. November 2011;7(11):720-727.
29. Patil, SA, Rustgi, A, Quezada, SM, Flasar, MH, Vandermeer, F, and Cross RK. Anti-TNF Therapy is Associated with Decreased Imaging and Radiation Exposure in Patients with Crohn’s Disease. Inflamm Bowel Dis. 2013;19(1):92-98.
30. Quezada, SM and Cross, RK. Association of Age at Diagnosis and Ulcerative Colitis Phenotype. Dig Dis Sci. 2012;57(9):2402-2407.
31. Faust, AH, Halpern, LF, Danoff-Burg, S, and Cross, RK. Psychosocial Factors Contributing to Inflammatory Bowel Disease Activity and Health-Related Quality of Life. Gastroenterology & Hepatology. March 2012;8(3):1-9.
32. McLean, LP, Shea-Donahue, T, and Cross, RK. Vedolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease. Immunotherapy. 2012;4(9):883-898.
33. Patil, S and Cross, RK. Where We’re Going, We Don’t Need Appointments: the Future of Telemedicine in IBD. (Summary of Krier, M, Kaltenbach, T, McQuaid, K, et al. Potential Us of telemedicine to provide outpatient care for inflammatory bowel disease. Am J Gastroenterol. 2011;106:2063-7). Inflamm Bowel Dis. 2012;18(11):2199-2200.
34. Quezada, SM, Steinberger, EK, and Cross, RK. Association of Age at Diagnosis and Crohn’s Disease Phenotype. Age Ageing. August 2012;0:1-4.
35. Patil, SA, Rustgi, A, Langenberg, P, and Cross, RK. Comparative Effectiveness of Anti-TNF Agents for Crohn’s Disease in a Tertiary Referral IBD Practice. Dig Dis Sci. 2013;58(1):209-215.
36. Ghazi, LJ, Patil, SA, Rustgi, A, Flasar, MH, Razeghi, S, and Cross, RK. Step Up versus Early Biologic Therapy for Crohn’s Disease in Clinical Practice. Inflamm Bowel Dis. 2013;19(7):1397-1403.
37. Syed, A, Cross, RK, and Flasar, MH. Anti-Tumor Necrosis Factor Therapy is Associated with Infections after Abdominal Surgery in Crohn’s Disease Patients. Am J Gastroenterol. 2013;108(4):583-593.
38. Quezada, SM and Cross, RK. To Yeast or Not to Yeast: A Probiotic Question. (Summary of Bourreille, A, Cadiot, G, Le Dreau, G, et al. Saccharomyces Boulardii for the Prevention of Relapse in Crohn’s Disease: Results of a Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial. Clin Gastroenterol Hepatol). Clin Gastroenterol Hepatol. 2013;11(8): 988-990.
39. McLean, LP, Cross, RK, and Shea-Donohue, T. Combined Blockade of IL-17A and IL-17F Prevents the Development of Experimental Colitis. (Summary of Wedebye Schmidt, EG, Larsen, HL, Kristensen, N et al. TH17 Cell Induction and Effects of IL-17A and IL-17F Blockade in Experimental Colitis. Inflamm Bowel Dis). Immunotherapy. 2013;5(9):1-3.
40. Razeghi, S, Halvorson, CR, Gaspari, AA, and Cross, RK. Successful Treatment of Localized Pyoderma Faciale in a Patient with Crohn’s Disease. Gastroenterology & Hepatology. 2013;9(8):541-544.
41. Cheng, FF, McLean, LP, and Cross, RK. What is the Role of Vedolizumab in the Era of Anti-TNF Agents. (Summary of Sandborn, WJ, Feagan, BG, and Rutgeerts, P et al. Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med). Ann Transl Med. 2014;2(1):1-4.
42. Flasar, M, Syed, A, and Cross, RK. “Letter to the Editor Kotze et al.: reply from Dr. Flasar, Mr. Syed, and Dr. Cross.” Am J Gastroenterol. 2014;109(1):139-140.
43. McLean, LP, Chun, J, and Cross, RK. “Right Lower Quadrant Pain in a Patient with IBD of Undetermined Type”. Clin Gastroenterol and Hepatol. 2014;12(4):A29-30.
44. McLean, LP and Cross, RK. “Adverse Events in IBD: To Stop or Continue Immune Suppressant and Biologic Treatment”. Expert Rev Gastroenterol Hepatol. 2014;8(3):223-240.
45. Patil, SA and Cross, RK. “Can You Hear Me Now? Frequent Telephone Encounters for Management of Patients with Inflammatory Bowel Disease. (Summary of Ramos-Rivers, CM, Regueiro, M, Vargas, EJ et al. Association Between Telephone Activity and Features of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol). Clin Gastroenterol Hepatol. 2014;12(6):995-996.
46. Ghazi, LJ, Lydecker, AD, Patil, SA, Rustgi, A, Cross, RK, and Flasar, MH. Racial Differences in Disease Activity and Quality of Life in Patients with Crohn’s Disease. Dig Dis Sci. 2014;50(10):2508-2513.
47. Osterman, MT, Aberra, FN, Cross, R, Liakos, S, McCabe, R, Shafran, I, Wolf, D, Hardi, R, Nessel, L, Brensinger, C, Gilroy, E, and Lewis, JD. A Randomized Controlled Trial of Mesalamine Dose Escalation for Ulcerative Colitis in Remission. Clin Gastroenterol Hepatol. 2014;12(11):1887-93.
48. Flasar, MH and Cross, RK. What is the need for comparative effectiveness studies in IBD? Expert Rev Gastroenterol Hepatol. Early online, 2014;8(8):851-4.
49. Zullow, S, Flasar, MH, Greenberg, D, Tracy, JK, Rustgi, A, and Cross, RK. A Health Survey of Gastroenterologist Prescribing Practices of Adalimumab for Treatment of Crohn’s Disease: Final Results. Gastroenterology & Hepatology. 2014;10(8):1-7.
50. Regueiro, MD, Greer, JB, Binion, DG, Schraut, WH, Goyal, A, Keilo, DJ, Cross, RK, Williams, ED, Herfarth, HH, Siegel, CA, Oikonomou, I, Brand, MH, Hartman, DJ, Tublin, ME, Davis, PL, Baidoo, L, Szigethy, E, and Watson, AR. The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. Inflamm Bowel Dis. 2014;20(10):1687-95.
51. Ghazi, LJ and Cross, RK. The Role of Telemedicine and E-Health in the Management of Inflammatory Bowel Disease: Improving Patient Outcomes. Smart Homecare Technology and Telehealth. 2015;3:17-24.
52. Quezada, SM, Rustgi, A, Jambaulikar, GD, and Cross, RK. Differential Response to Microbial Antigens by Age of Diagnosis in Patients with Crohn’s Disease. Clin Exp Gastroenterol. 2015;8:169-74.
53. Le, P, Greer, J, Oikonomou, I, Schraut, W, Siegel, C, Cross, RK, Holubar, S, Tinsley, A, Koltun, W, Binion, D, Regueiro, M. Previous Cancer in a Patient with Crohn’s Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis. 2015; 21(6): 1401-6.
54. Cross, RK, Jambaulikar, Guruprasad, Langenberg, P, Tracy, JK, Collins, JF, Katz, J, Regueiro, M, Schwartz, DA, and Quinn, CC. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Design and Implementation of Randomized Clinical Trial. Contemp Clin Trials. 2015;132:132-44.
55. George, LA, Gadani, A, Cross, RK, Jambaulikar, G, and Ghazi, LJ. Psoriasiform Skin Lesions are Caused by Anti-TNF Agents used for the Treatment of Inflammatory Bowel Disease. Dig Dis Sci. 2015; 60(11): 3424-30.
56. Hagan, M and Cross, RK. Vedolizumab for Treating Crohn’s Disease and Ulcerative Colitis. Expert Opin Drug Saf. 2015; 14(9): 1-8
57. Huang, C, Haritunians, T, Okou, DT, Cutler, DJ, Zwick, ME, Taylor, KD, Datta, LW, Maranville, JC, Alexander, JS, Baldassano, RN, Cho, JH, Cross, RK, Dassopoulus, T, Dhere, TA, Duerr, RH, Hanson, JS, Hou, JK, Hussain, SZ, Isaacs, KL, Kachelries, KE, Kader, H, Kappelman, M, Katz, J, Kirschner, BS, Kummerle, JF, Kumar, A, Kwon, JH, Lazarev, M, Mannon, P, Moulton, DE, Osuntokun, BO, Patel, A, Rioux, JD, Rotter, JI, Saeed, S, Scherl, EJ, Silverberg, MS, Silverman, A, Targan, SR, Valentine, J, Wang, M, Zonca, M, Simpson, CL, Bridges, SL, Kimberly, RP, Rich, SS, Di Rienzo, A, Kao, LWH, McGovern, DPB, Brant, SR, and Kugathasan, S. Characterization of genetic loci that affect suspectibility to inflammatory bowel disease in African Americans. Gastroenterology. 2015; 149(6): 1575-86.
58. Cross, RK. Which patients with inflammatory bowel disease should receive combination therapy? Expert Rev Gastroenterol Hepatol. 2015; 9(6): 715-717.
59. Sunseri, WM, Kugathasan, S, Keljo, DJ, Greer, JB, Ranganathan, S, Cross, RK, Siegel, CA, and Regueiro, MD. IBD LIVE Case Series-Case 3: Very Early-Onset Inflammatory Bowel Disease: When Genetic Testing Proves Beneficial. Infamm Bowel Dis. 2015; 21(12): 2958-68.
60. Flasar, M, Chao, J, Ozbay, AB, Skup, M, Lu, M, and Cross, R. Biological and Immunomodulator Use in Crohn’s Disease in a Medicaid Population. Inflamm Bowel Dis. 2016; 22(5): 1056-64.
61. Gulati, A, Clarke, K, Greer, J, Binion, D, Brand, M, Farraye, F, Cross, R, Baidoo, L, Schraut, W, Hartman, D, Regueiro, M. IBD Live Case Series-Case 4: Worms in IBD: Friend or Foe. Inflamm Bowel Dis. 2016; 22(6): 1462-72.
62. McLean, LP and Cross, RK. Integrin Antagonists as Potential Therapeutic Options for the Treatment of Crohn’s Disease. Expert Opinion on Investigational Drugs. 2016; 25(3): 263-273.
63. McLean, LP and Cross, RK. Pharmacodynamic assessment of vedolizumab for ulcerative colitis. Expert Opinion on Drug Metabolism and Toxicology. 2016; DOI: 10.1080/17425255.2016.1181171.
64. Quezada, SM, Langenberg, P, and Cross, RK. Cigarette smoking adversely affects disease activity and disease-specific quality of life in patients with Crohn’s disease at a tertiary referral center. Clinical and Experimental Gastroenterology. 2016; 2016 (9): 307-310.
65. Rajan, D, Greer, JB, Regueiro, MD, Baidoo, L, Binion, DG, Herfarth, HH, Siegel, CA, Hartman, DJ, Farraye, FA, Koutrabakis, IE, Brand, MH, Williams, ED, Goyal, A, and Cross, RK. IBD LIVE Case Series-Case 6: Persistent Skin Lesions in a Patient with Crohn’s Disease: You Hear Hoof Beats and Discover a Zebra. Inflamm Bowel Dis. 2016; 22(11): 2754-2764.
66. Stidham, RW and Cross, RK. Endoscopy and cross-sectional imaging for assessing Crohn’s disease activity. Tech Gastrointest Endosc. 2016 Jul; 18(3): 123-130.
67. Brant, SR, Okou, DT, Simpson, CL, Cutler, DJ, Haritunians, T, Bradfield, JP, Chopra, P, Prince, J, Begum, F, Kumar, A, Huang, C, Venkateswaran, S, Wei, Z, Thomas, K, Herrington, L, Klapproth, JA, Quiros, A, Liu, Z, Alexander, JS, Baldassano, RN, Dudley-Brown, S, Cross, RK, Dassopoulos, T, Dhere, TA, Dryden, GT, Hanson, JS, Hou, JK, Hussain, SZ, Denson, LA, Hyams, J, Mack, D, Isaacs, KL, Kader, H, Kappelman, MD, Katz, J, Kellermayer, R, Kirschner, BS, Kuemmerle, JF, Kwon, JH, Li, E, Mannon, P, Moulton, DE, Newberry, RD, Osuntokun, BO, Patel, A, Saeed, S, Targan, SR, Valentine, J, Wang, M, Lazarev, M, Zonca, M, Datta, LW, Rioux, JD, Duerr, RH, Silverberg, MS, Cho, JH, Hakonarson, H, Zwick, ME, McGovern, DPB, Kugathasan, S. Genome-wide Association Identifies African-Specific Susceptibility Loci in African Americans with Inflammatory Bowel Disease. Gastroenterology. 2017; 152(1):206-217 e202.
68. Cross, RK and Kane, S. Integration of Telemedicine Into Clinical Gastroenterology and Hepatology. Clin Gastroenterol Hepatol. 2017; 15(2): 175-181.
69. Allen, J, Szigethy, EM, Reiss, M, Cohen, W, Perera, LP, Brillstein, L, Cross, RK, Schwartz, DA, Kosinski, LR, Colton, JB, LaRusso, E, Atreja, A, and Regueiro, M. White Paper AGA: The Impact of Psychosocial Factors on the Care of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2017; 15(7): 986-997.
70. Zullow, S, Jambaulikar, G, Rustgi, A, Quezada, S, and Cross, RK. Risk Factors for Vitamin D Deficiency and Impact of Repletion in a Tertiary Care Inflammatory Bowel Disease Population. Dig Dis Sci. 2017 Aug; 62(8): 2072-2078.
71. Christian, KE, Jambaulikar, GD, Hagan, MN, Syed, AM, Briscoe, JA, Brown, SA, Campbell, EV, Gadani, AB, and Cross, RK. Predictors of Early Readmission in Hospitalized Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 Nov; 23(11): 1891-1897.
72. Patil, SA and Cross, RK. Medical versus Surgical Management of Penetrating Crohn’s Disease: the Current Situation and Future Perspectives. Expert Rev Gastroenterol Hepatol. 21 Jun 2017: 1-6. .
73. Cross, RK. Review Article: Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild to Moderate Ulcerative Colitis. Inflamm Bowel Dis. 2017; 23(10):1689-1701.
74. Bertha, M, Vasantharoopan, A, Kumar, A, Bruce, B, Prince, J, Hofmekler, T, Okou, D, Chopra, P, Wang, G, Sauer, C, Landers, CJ, Hussain, SZ, Cross, RK, Baldassano, RN, Kappelman, MD, Katz, J, Alexander, JS, Kirschner, BS, Moulton, DE, Osuntokun, BO, Patel, A, Saeed, S, Klapproth, JA, Dhere, TA, Dubinskey, MC, McGovern, D, and Kugathasan, S. IBD Serology and Disease Outcomes in African-Americans with Crohn’s Disease. Inflamm Bowel Dis. 2017 Dec 19; 24(1): 209-216.
75. Wong, U and Cross, RK. Primary and Secondary Non-Response to Infliximab: Mechanisms and Countermeasures. Expert Opinion on Drug Metabolism and Toxicology. 20 Jun 2017; 10: 1-8. .
76. Engels, M, Cross, RK, and Long, MD. Exercise in Patients with Inflammatory Bowel Disease: Current Perspectives. Clin Exp Gastroenterol. 22 Dec 2017; 11:1-11. doi: 10.2147/CEG.S120816.
77. Christian, K and Cross, RK. Improving Outcomes in Patients with Inflammatory Bowel Disease Through Integrated Multi-Disciplinary Care-the Future of IBD Care. Clin Gastroenterol Hepatol. 2018; 16(11): 1708-1709.
78. Patil, SA and Cross, RK. Current Landscape of Telemedicine Practice in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(9): 1910-1917. 10.1093/ibd/izy113.
79. Abutaleb, A, Buchwald, A, Chudy-Onwugaje, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Quinn, CC, Jambaulikar, G, Beaulieu, DB, Horst, S, and Cross, RK. Inflammatory Bowel Disease Telemedicine Clinical Trial: Impact of Weekly Educational Text Messages on Disease-Specific Knowledge Over One Year. Inflamm Bowel Dis. 2018; 24 (10): 2191-2197. .
80. Eluri, S, Cross, RK, Martin, C, Weinfurt, KP, Flynn, KE, Long, MD, Chen, W, Anton, K, Sandler, RS, and Kappelman, MD. Inflammatory Bowel Diseases Can Adversely Impact Domains of Sexual Function Such as Satisfaction with Sex Life. Dig Dis Sci. 2018; 63(6): 1572-1582.
81. Chudy-Onwugaje, K, Abutaleb, A, Buchwald, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Horst, S, Beaulieu, DB, Quinn, CC, Jambaulikar, G, and Cross, RK. Age Modifies the Association between Depressive Symptoms and Adherence to Self-Testing with Telemedicine in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018; 24(12): 2648-2654. .
82. Proksell, SS, Greer, JB, Theisen, BK, Davis, PL, Rosh, JR, Keljo, DJ, Goyal, A, Shah, SA, Brand, MH, Herfarth, HH, Cross, RK, Siegel, CA, Kolturn, WA, Isaacs, KL, and Regueiro, MD. IBD LIVE Case Series: Case 9: Do Race and Extraintestinal Manifestations Affect Treatment of Severe Crohn’s Colitis? Inflamm Bowel Dis. 2018 Mar 19; 24(4): 698-713.
83. Dubinsky, MC, Cross, RK, Sandborn, WJ, Long, M, Song, X, Shi, N, Ding, Y, Eichner, S, Pappalardo, B, Ganguli, A, and Wang, A. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Apr 13. DOI; 10.1093/ibd/izy065.
84. Cross, RK and Herfarth, H. Is there a role for thiopurines in IBD? Am J Gastroenterol. 2018 Aug; 113(8): 1121-1124. Doi: 10.1038/s41395-018-0175-8.
85. Patil, SA and Cross, RK. More skin in the game: Screening for skin cancer in IBD patients. Dig Dis Sci. 2018 Oct; 63(10): 2497-2499. DOI; 10.1007/s10620-018-5136-y
86. Herfarth, H, Barnes, EL, Valentine, JF, Hanson, J, Higgins, PDR, Isaacs, KL, Jackson, S, Osterman, MT, Anton, K, Ivanova, A, I, Long, MD, Martin, C, Sandler, RS, Abraham, B, Cross, RK, Dryden, G, Fischer, M, Harlan, W, Levy, C, McCabe, R, Polyak, S, Saha, S, Williams, E, Yajnik, V, Hamilton, F, Serrano, J, James, S, Sands, BE and Lewis, JD. Methotrexate is not superior to placebo in maintaining steroid-free remission in ulcerative colitis. Gastro. 2018 Octo; 155(4): 1098-1108. doi: 10.1053/j.gastro.2018.06.046.
87. Voit, Antanina, Cross, RK, Bellavance, E, and Bafford, AC. Financial toxicity in Crohn’s disease. J Clin Gastroenterol. 2018 Oct 24. Doi: 10.1097/MCG. 0000000000001139.
88. George, L and Cross, RK. De Jong, et al. Telemedicine for management of inflammatory bowel disease (MyIBDcoach): a pragmatic, multicenter, randomized controlled trial. Lancet. 2017 Sep 2; 390 (10093): 959-968. BMJ Evidenced-Based Medicine. 2019; 24 (1): 37-38. 10.1136/bmjebm-2018-111000.
89. Cross, RK, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Collins, JF, Katz, J, Ghazi, L, Patil, SA, Quezada, SM, Russman, K, Riaz, M, Jambaulikar, G, Sivasailam, B, and Quinn, C. A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Am J Gastroenterol. 2018 March; 114(3):472-482. doi: 10.1038/s41395-018-0272-8.
90. Patil, SA, Flasar, MH, Lin, J, Lingohr-Smith, M, Skup, M, Wang, S, Chao, J, and Cross, RK. Reduced Imaging Radiation Exposure Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn’s Disease. Dig Dis Sci. 2019 Jan; 64(1): 60-67. doi: 10.1007/s10620-018-5322-y.
91. Quezada, SM, McLean, LP, and Cross, RK. Adverse Events in IBD: The 2018 Update. Expert Rev Gastroenterol Hepatol. 2018 Dec; 12(12):1183-1191. 10.1080/17474124.2018.1545574.
92. Chudy-Onwugaje, KO, Christian, KE, Farraye, FA, and Cross, RK. A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflamm Bowel Dis. 2018 Nov 15. .
93. Bilgrami, Z, Abutaleb, A, Chudy-Onwugajae, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, SA, Quezada, SM, Russman, KM, Quinn, CC, Jambaulikar, G, Beaulieu, DB, Horst, S, and Cross, RK. Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activation and Self-Efficacy. Dig Dis Sci. 2020; 65(1): 96-103. DOI 0.1007/s10620-018-5433-5. Correction to: Effect of TELEmedicine for Inflammatory Bowel Disease on Patient Activiation and Self-Efficacy. Dig Dis Sci. 2020; 65(2): 668. 10.1007/s10620-019-05953-4
94. Quezada, SM and Cross, RK. Cannabis and turmeric as complementary treatments for IBD and other digestive diseases. Curr Gastroenterol Rep. 2019 Jan 11; 21(2):2. Doi: 10.1007/s11894-019-0670-0.
95. Ko, CW, Singh, S, Feuerstein, JD, Falck-Ytter, C, Falck-Ytter, Y, and Cross, RK. American Gastroenterological Association Institute Guideline on the Management of Mild-to-Moderate Ulcerative Colitis. Gastro. 2019 Feb; 156(3): 748-764. doi: 10.1053/j.gastro.2018.12.009.
96. Caldera, F, Hayney, MS, and Cross, RK. Using number needed to harm to put the risk of Herpes Zoster from tofacitinib in perspective. Inflamm Bowel Dis. 2019 May; 25(6):955-957. Doi: 10.1093/ibd/izy387.
97. Schad, CA, Cross, RK, Syed, A, Lonasko, S, and Bafford, AC. Early postoperative anti-TNF therapy does not increase complications following abdominal surgery in patients with Crohn’s disease. Dig Dis Sci. 2019 Jul; 64(7): 1959-1966. Doi: .
98. Kinnucan, J, Binion, D, Cross, R, Evans, E, Harlen, K, Matarese, L, Mullins, A, O’Neal, B, Reiss, M, Scott, FI, Weaver, A, and Rosenberg, J. Inflammatory Bowel Disease Care System Referral Pathways. Gastro. 2019 Apr 10. pii: S0016-5085(19)35665-3. doi: 10.1053/j.gastro.2019.03.064
99. Wong, U and Cross, RK. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. Expert Opinion On Investigational Drugs. 2019; 28(5): 473-479. DOI: 10.1080/13543784.2019.1597053
100. Christian, KE, Russman, KM, Rajan, DP, Barr, EA, and Cross, RK. Gender Differences and Other Factors Associated with Weight Gain Following Initiation of Infliximab: A Post-Hoc Analysis of Clinical Trials. Inflamm Bowel Dis. 2020; 26(1): 125-131.
101. Quinn, CC, Chard, S, Roth, EG, Eckert, JK, Russman, KM, and Cross, RK. The Telemedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) Clinical Trial: Qualitative Assessment of Participants’ Perceptions. J Med Internet Res. 2019; 21(6): e14165.
102. Bhattacharya, S and Cross, RK. Is endoscopic remission in ulcerative colitis still good enough? Inflamm Bowel Dis. 2019; 25(11): 1729-1730. .
103. Scott, FI, Rubin, DT, Kugathasan, S, Bousvaros, A, Elson, CO, Newberry, RD, Melmed, GY, Pekow, J, Fleshman, JW, Boyle, BM, Mahadevan, U, Cannon, LM, Long, MD, Cross, RK, Ha, CY, Lasch, KL, Robinson, AM, Rafferty, JF, Lee, JJ, Cowden, DK, Weaver, A, Shtraizent, N, Honig, G, Hurtado-Lorenzo, A, and Heller, CA. Challenges in IBD Research: Pragmatic Clinical Research. Inflamm Bowel Dis. 2019; 25(S2): S40-47.
104. George, L and Cross, RK. How do we sequence biologic therapies in 2019? Inflamm Bowel Dis. 2020; 26(4): 617-18.
105. Shen, B, Kochhar, G, Navaneethan, U, Farraye, FA, Schwartz, DA, Iacucci, M, Bernstein, CN,Dryden, G, Cross, RK, Bruining, DH, Kobayashi, T, Lukas, M, Shergill, A, Bortlik, M, Lan, N, Lukas, M, Tang, SJ, Kotze, PG, Kiran, RP, Dulai, PS, El-Hachem, S, Coelho-Prabhu, N, Thakkar, S, Mao, R,Chen, G, Zhang, S, González Suárez, B, Gonzalez Lama, Y, Silverberg, MS, Sandborn, WJ. Practical Guideline on Endoscopic Therapy of Crohn’s Disease Strictures: An Expert Consensus from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020. Published Online January 16, 2020.
S2468-1253(19)30366-8.
106. Haac, BE, Nemirovsky, A, Teeter, W, Geyer, A, Birkett, RT, Cross, RK, Engels, M, Stein, DM, and Bafford, AC. Injury Characteristics and Outcomes of Patients with Inflammatory Bowel Disease after Trauma: A Propensity Score Matched Analysis. Inflamm Bowel Dis. In press.
107. Cross, RK, Chiorean, M, Vekeman, F, Xiao, Y, Wu, E, Chao, J, and Wang, A. Assessment of the real-world safety profile of vedolizumab using the United States Food and Drug Administration adverse event reporting system. PLOS ONE. In press.
108. Wong, U and Cross, RK. Are inflammatory bowel disease patients with diabetes mellitus at increased risk for poor outcomes including greater healthcare utilization? Inflamm Bowel Dis. 2020 Jan 16. pii: izz306. doi: 10.1093/ibd/izz306.
109. Stoleru, G, George, L, Cross, RK, and Wong, U. An unusual presentation of Baker’s cyst rupture in an inflammatory bowel disease patient. Case Reports in Medicine. 2020; 2020 (3140958).
110. Bafford, A and Cross, RK. Risk of venous thromboembolism in patients with inflammatory bowel disease extends beyond hospitalization. Inflamm Bowel Dis. 29 January 2020. 10.1093/ibd/izaa003
111. Kamal, N, Bookwater, A, Foss, R, and Cross, RK. Pyostomatitis vegetans: An unusual oral manifestation of inflammatory bowel diseas. Am J Gastroenterol. In press.
112. Rossman, L and Cross, RK. Just say no…to the nocebo effect. Inflamm Bowel Dis. 2020; 26(5):660. 10.1093/ibd/izaa021
113. Schliep, M, Chudy-Onwugaje, K, Abutaleb, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, KT, Ghazi, L, Patil, SA, Quezada, S, Russman, K, Horst, S, Beaulieu, D, Quinn, C, Jambaulikar, G, and Cross, RK. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) does not improve depressive symptoms or general quality of life compared to standard care at tertiary referral centers. Crohn’s & Colitis 360. 31 January 2020; 2(1).
114. Bhattacharya, S and Cross, RK. Therapeutic updates for moderate to severe ulcerative colitis. Dig Med Res. 2020; 3:10. doi: 10.21037/dmr.2020.01.04.
115. Haac, BE, Rubin, JN, Christian, K, Merechi, F, Wong, U, Cross, RK, Patil, SA and Bafford, AC. Case of invasive metastatic breast cancer mimicking Crohn’s disease. Global Surgery Case Reports. 2020; 1(1):1-3. DOI: 10.31487/j.GSCR.2019.01.04
116. Bhattacharya, S, Wong, U, and Cross, RK. Telemedicine in the management of inflammatory bowel disease: An update. Smart Homecare Technol Telehealth. 2020; 7:9-17.
117. Chudy-Onwugaje, K, Mamunes, AP, Schwartz, DA, Horst, S, and Cross, RK. Predictors of high health care utilization in patients with inflammatory bowel disease within 1 year of establishing specialist care. Inflamm Bowel Dis. In press.
118. Chiorean, M, Afzali, A, Cross, RK, Macaulay, D, Griffith, J, Wang, A, and Garcia-Horton, V. Economic outcomes of inflammatory bowel disease patients switching to a second anti-tumor necrosis factor or vedolizumab. Crohn’s & Colitis 360. In press.
119. Osterman, MT, Scott, FI, Fogt, FF, Gilroy, ED, Parrott, S, Galanko, J, Cross, R, Moss, A, Herfarth, HH, and Higgins, PDR. Endoscopic and histological assessment, correlation, and relapse in clinically quiescent ulcerative colitis (MARQUEE). Inflamm Bowel Dis. 2020 Mar 14. pii: izaa048. doi: 10.1093/ibd/izaa048.
120. George, LA, Dominic, MR, and Cross, RK. Integration of telemedicine into clinical practice for inflammatory bowel disease. Curr Opin Gastroenterol. In press.
121. Syed, N, Tolaymat, M, Brown, SA, Sivasailam, B, and Cross, RK. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared to reactive and clinical monitoring. Crohn’s & Colitis 360. In press.
Non-Peer-Reviewed Journal Articles
Cross, RK and Wilson, KT. Nitric oxide in Inflammatory Bowel Disease. Inflamm Bowel Dis 2003;9:179-89.
1. Flasar, M, Cross, RK, and Goldberg, E. Abdominal Pain. Prim Care Clin Office Pract 2006;33:659-84.
2. Joshi, G, Cross, RK, and Flasar, MH. Race and Inflammatory Bowel Disease. Practical Gastroenterology. 2009;33(1):23-33.
3. Cross, RK. Book Review of Ulcerative Colitis: The Complete Guide to Medical Management. Practical Gastroenterology. 2012;36(3):62.
4. Patil, SA and Cross, RK. Update in the Management of Extraintestinal Manifestations of Inflammatory Bowel Disease. Curr Gastroenterol Rep 2013;15(3):314.
5. Stoddard, PB, Ghazi, LJ, Wong-You-Cheong, J, Cross, RK, and Vandermeer, FQ. Magnetic Resonance Enterography: State of the Art. Inflamm Bowel Dis 2015;21(1):229-39.
6. Ghazi, LJ, Patil, SA, and Cross, RK. Sexual Dysfunction in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015; 21(4):939-47.
7. Quezada, SM, Briscoe, J, and Cross, RK. Complementary and Alternative Medicine. Inflamm Bowel Dis. 2016; 22(6): 1523-30.
8. Afzali, A and Cross, RK. Racial and ethnic minorities with Inflammatory Bowel Disease in the United States: A systematic review of disease characteristics and differences. Inflamm Bowel Dis. 2016; 22(8): 2023-40.
9. Cross, RK. Book Review of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Gastroenterology. 2017.
10. George, LA, and Cross, RK. Remote monitoring and telemedicine in IBD, are we there yet? Curr Gastroenterol Rep. 2020; 22(12).
11.
Web Based Journal Articles
1. Selaru, F, Drachenberg, C, and Cross, RK. A 28 year old man with liver failure. Gastroenterology. 2007 Nov;133(5):e1-3.
Book Chapters
Flasar, M and Cross, RK. Medical Therapy of Ulcerative Colitis. Handbook of Inflammatory Bowel Disease. Baltimore: Lippincott Williams & Wilkins, 2010. 37-45.
1. Landau, T and Cross, RK. Gastrointestinal Tract and Rheumatic Disease, Rheumatology. 5th ed. Philadelphia: Mosby Elsevier, 2010. 321-327
2. Ghazi, L and Cross, RK. Benefits of Enhancing Patient-Medical Professional Interface. Advanced Therapy in IBD. Shelton: People’s Medical Publishing House, 2011. 53-59.
3. Quezada, S and Cross, RK. Telemedicine for Chronic Digestive Diseases: A Systematic Qualitative Review, Telemedicine Techniques and Applications. Rijeka, Croatia: InTech, 2011. 347-362.
4. Quezada, S and Cross, RK. The Role of Telemedicine for Management of Ulcerative Colitis, Medical Therapy of Ulcerative Colitis. New York: Springer Science + Business Media, 2014. 335-43.
5. Hagan, M and Cross, RK. Gastrointestinal Tract and Rheumatic Disease, Rheumatology. 6th ed. Philadelphia: Mosby Elsevier, 5th ed. Philadelphia: Mosby Elsevier, 2014. 279-285.
6. Quezada, SM and Cross, RK. What About Alternative Therapies I Can Try? Dietary Supplements, Probiotics, Prebiotics and Alternative Therapies in IBD. Inflammatory Bowel Disease: A Point of Care Clinical Guide. Switzerland: Springer International Publishing, 2015. 107-117.
7. Engels, M and Cross, RK. Medical Management of Crohn’s Disease. Crohn’s Surgery. In press.
8. Wong, U and Cross, RK. Non-infectious and Non-malignant Complications of Biologics. Treatment of Inflammatory Bowel Disease with Biologics. Switzerland: Springer International Publishing AG 2018. 231-260.
Abstracts and/or Proceedings
1. Cross, RK, Wilson, KT, and Binion, DG. High Prevalence of Polypharmacy in Crohn’s Disease. American College of Gastroenterology, Baltimore, Maryland, October 2003.
2. Cross, RK, Wilson, KT, and Binion, DG. Narcotic Use in Patients with Crohn’s Disease. American College of Gastroenterology, Baltimore, Maryland, October 2003.
3. Knox, JF, Rose, D, Emmons, J, Podoll, J, Saeian, K, Attila, T, Cross, RK, and Binion, DG. Colesevelam for the Treatment of Bile Acid-Induced Diarrhea in Crohn’s Disease Patients Intolerant of Cholestyramine. American Gastroenterological Association, New Orleans, Louisiana, May 2004.
4. Flasar, M, Harris, A, Hungerford, L, and Cross, RK. Risk of Lymphoma in Patients with Inflammatory Bowel Disease (IBD) a Systematic Qualitative Review. American Gastroenterological Association, Chicago, Illinois, May 2005.
5. Ramanujam, S, Knox, JF, Emmons, J, Otterson, MF, Cross, RK, Csuka, ME, and Binion, DG. Leflunomide is Effective as a Steroid Sparing, Maintenance Therapy for Moderate to Severe Crohn’s Disease Patient Intolerant to Standard Immunomodulator Therapy. American Gastroenterological Association, Chicago, Illinois, May 2005.
6. Beaulieau, DB, Otterson, MF, Newcomer, J, Kuhlmann, R, Abu-Hajir, M, Emmons, J, Knox, JF, Cross, RK, and Binion, D. IBD Pregnancy Complications and Outcomes in the Era of Immunomodulator and Biologic Therapy: a Tertiary Referral Center Experience. American Gastroenterological Association, Chicago, Illinois, May 2005.
7. Barboi, AC, Spinelli, K, Sudakoff, GS, Kugathasan, S, Cross, RK, Jaradeh, SS, Otterson, MF, Knox, JF, Emmons, J, Brandenburg, H, and Binion, D. Autonomic Dysfunction in Inflammatory Bowel Disease (IBD) Correlates with Diminished Quality of Life, Impaired Motility and Disability. American Gastroenterological Association, Chicago, Illinois, May 2005.
8. Ramanujam, S, Knox, JF, Emmons, J, Hatoum, OA, Otterson, MF, Cross, RK, Csuka, ME, and Binion, DG. Leflunomide Treatment of Moderate to Severe Ulcerative Colitis Patients Intolerant to Standard Immunomodulator Therapy. American Gastroenterological Association, Chicago, Illinois, May 2005.
9. Williams, JB, Cross, RK, Thameen, D, Knox, JF, Emmons, J, Otterson, MF, and Binion, DG. Long-Term Infliximab Maintenance Infusion Regimens and Rates of Hospitalization, Surgery, and Disability in Crohn’s Disease Patients. American Gastroenterological Association, Chicago, Illinois, May 2005.
10. Cross, RK, Arora, M, Sharma, K, and Finkelstein, J. Home Automated Telemanagement in Inflammatory Bowel Disease. IASTED International Conference on Telehealth (Telehealth 2005), July 2005, Banff, Canada
11. Cross, RK and Finkelstein, J. Feasibility and Patient Acceptance of a Home Telemanagement System in Inflammatory Bowel Disease. American Gastroenterological Association, Los Angeles, California, May 2006.
12. Donovan, M, Lunney, K, Carter-Pokras, O, and Cross, RK. Prescribing Patterns and Awareness of Adverse Effects of Infliximab: A Health Survey of Gastroenterologists. American Gastroenterological Association, Los Angeles, California, May 2006.
13. Lapshin, O, Cross, RK, and Finkelstein, J. Subjective Reasons for Noncompliance with Medical Regimen in Inflammatory Bowel Disease Patients. International Society For Pharmacoeconomics and Outcomes Research 11th Annual International Meeting, Philadelphia, Pennsylvania, May 2006.
14. Castro, H, Cross, RK, and Finkelstein, J. Using a Home Automated Telemanagement (HAT) System: Experiences and Perceptions of Patients with Inflammatory Bowel Disease. American Medical Informatics Association, Washington, D.C., November 2006
15. Flasar M, Quezada S, Bijpuria P, Joshi G, Wasan S, Cross R. Differences in Medical Treatments between African Americans and Caucasians with Inflammatory Bowel Disease: A Retrospective Cohort Study. American Gastroenterological Association, Los Angeles, California, May 2006.
16. Flasar M, Quezada S, Bijpuria P, Joshi G, Wasan S, Cross RK. Racial Differences in Disease Extent and Severity in Patients with Ulcerative Colitis: A Retrospective Cohort Study. American Gastroenterological Association, Washington, D.C., May 2007.
17. Cross, RK, Cheevers, N, Lambert, K, Steele, AG, Stozhkov, P, Finkelstein, J, Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). American Gastroenterological Association, San Diego, California, May 2008.
18. Samimi, R, Flasar, MH, Tracy, K, and Cross, RK. Outcome of Medical Treatment of Stricturing and Penetrating Crohn’s Disease: A Retrospective Study. American College of Gastroenterology, Orlando, Florida, October 2008.
19. Finkelstein J, Wood J, Cross R. Design and Implementation of Home Automated Telemanagement System for Patients with Ulcerative Colitis. International Conference on eHealth, Telemedicine, and Social Medicine: eTELEMED 2009, Cancun, Mexico. February 1-7, 2009.
20. Patil, S, Rustgi, A, and Cross, RK. Choice of Anti-TNF Agents Does Not Effect Clinical Outcomes in Patients with Crohn’s Disease Evaluated at a Referral Center. American Gastroenterological Association, New Orleans, Louisiana, May 2010.
21. Cross, RK, Cheevers, N, Rustgi, A, Hanahan, A, Steele, AG, Lydecker, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis (UC HAT). American Gastroenterological Association, New Orleans, Louisiana, May 2010.
22. Faust, AH, Halpern, L, and Cross, RK. The Impact of Coping Style and Social Constraint on Adherence, Quality of Life, and Disease Activity in Patients with Inflammatory Bowel Disease. American Gastroenterological Association, New Orleans, Louisiana, May 2010.
23. Ghazi, L, Cross, RK, Lydecker, A, and Flasar, M. Quality of Life, Disease Activity, and Flares in Crohn’s Disease Differ by Race Over Time? American College of Gastroenterology, San Antonio, Texas, October 2010.
24. Ghazi, L, Cross, RK, Lydecker, A, and Flasar, M. Do Quality of Life, Disease Activity, and Flares in Ulcerative Colitis Differ by Race Over Time? American College of Gastroenterology, San Antonio, Texas, October 2010.
25. Ghazi, L, Patil, S, Flasar, M, and Cross, RK. Is the Natural History of Crohn’s Disease Altered by Immune Suppressant or Biologic Drug Use? American College of Gastroenterology, San Antonio, Texas, October 2010.
26. Quezada, S, and Cross, RK. Impact of Age at Diagnosis and Ulcerative Colitis Disease Extent. American College of Gastroenterology, San Antonio, Texas, October 2010.
27. Quezada, S, and Cross, RK. Impact of Age at Diagnosis and Crohn’s Disease Phenotype American College of Gastroenterology, San Antonio, Texas, October 2010.
28. Flasar, M, Mulani, P, Yang, M, Chao, J, Lu, M, and Cross, RK. Racial Differences in Use of Biologics for Crohn’s Disease in a Medicaid Population. American College of Gastroenterology, San Antonio, Texas, October 2010.
29. Patil, S, Ghazi, L, Rustgi, A, Cross, RK, and Flasar, M. Response to Biologic Therapy in Crohn’s Disease Does Not Differ by Race. American College of Gastroenterology, San Antonio, Texas, October 2010.
30. Patil, S, Rustgi, A, Vandermeer, F, and Cross, RK. Use of Anti-TNF Therapy is Associated with Decreased Utilization of Diagnostic Imaging and Radiation Dose in Crohn’s Disease. American College of Gastroenterology, San Antonio, Texas, October 2010.
31. Quezada, S, Cheevers, N, Rustgi, A, and Cross, RK. Serologic Response to Microbial Antigens does not Differ by Age of Diagnosis in Patients with Inflammatory Bowel Disease. American Gastroenterological Association, Chicago, Illinois, May 2011.
32. Cross, RK, Cheevers, N, Rustgi, A, Hanahan, A, Steele, A, Lydecker, A, Langenberg, P, and Finkelstein, J. A Randomized, Controlled Trial of Home Telemanagement in Patients with Ulcerative Colitis, American Gastroenterological Association, Chicago, Illinois, May 2011
33. Syed, A, Cross, RK, and Flasar, MH. Preoperative Use of α-TNF Therapy in Crohn’s Disease Patients is Associated with Increased Infectious and Surgical Complications, American Gastroenterological Association, Chicago, Illinois, May 2011
34. Patil, S, Quezada, S, Rustgi, A, and Cross, RK. Risk Factors for High Dose Radiation Exposure in Crohn’s Disease. American College of Gastroenterology, National Harbor, Maryland, October 2011
35. Patil, S, Rustgi, A, Quezada, S, Flasar, MH, Vandermeer, F, and Cross, RK. Anti-TNF Agents Decrease Imaging and Radiation Exposure in Patients with Crohn’s Disease. American College of Gastroenterology, National Harbor, Maryland, October 2011
36. Razeghi, S, Halvorson, C, Gaspari, A, and Cross, RK. Successful Treatment of Localized Pyoderma Faciale in a Patient with Crohn’s Disease. American College of Physicians, Baltimore, Maryland, May 2012
37. Patil, S, Flasar, MH, Rustgi, A, Watson, J, Betteridge, J, Szeto, W, Cheevers, N, Yang, M, Chao, JD, Mulani, P, and Cross, RK. Predictors of a Complicated Disease Course in Crohn’s Disease, American Gastroenterological Association, San Diego, California, May 2012
38. Zullow, S, Rustgi, A, and Cross, RK. Risk Factors for Vitamin D Deficiency and Impact of Repletion in a Tertiary Referral Inflammatory Bowel Disease Population, American Gastroenterological Association, San Diego, California, May 2012
39. Kugathasan, S, Dhere, TA, Saeed, SA, Denson, L, Cross, R, Landers, CJ, McGovern, DP, Walters, TD, and Dubinsky, M. Unique Antimicrobial and Genetic Profiles in African Americans with Crohn’s Disease Suggest Underlying Mechanistic Differences, American Gastroenterological Association, San Diego, California, May 2012
40. Flasar, MH, Blanchette, C, St. Charles, M, and Cross, RK. Lower Infliximab Use in African American Compared to Caucasian IBD Patients: Analysis of a Large U.S. Comparative Hospital Database, American College of Gastroenterology, Las Vegas, Nevada, October 2012
41. Patil, S, Rustgi, A, Watson, J, Betteridge, J, Szeto, W, Cheevers, N, Flasar, M, Skup, M, Yang, M, Chao, J, Mulani, P, and Cross, RK. Predictors of Disability in Patients with Crohn’s Disease, American College of Gastroenterology, Las Vegas, Nevada, October 2012
42. Cross, RK, Flasar, M, Patil, S, Lin, J, Yan, M, Mulani, P, and Chao, J. Use of Anti-TNF Agents in Crohn’s Disease is Associated with Larger Reductions in Diagnostic Imaging and Radiation Doses Compared with Systemic Steroids in the Year Following Initiation of Therapy, American College of Gastroenterology, Las Vegas, Nevada, October 2012
43. Quezada, S, Rustgi, A, and Cross, RK. Differential Response to Microbial Antigens by Age of Diagnosis in Crohn’s Disease, American College of Gastroenterology, Las Vegas, Nevada, October 2012
44. Kappelman, M, Martin, C, Weinfurt, K, Flynn, K, Chen, WL, Anton, K, Cross, RK, Long, M, and Sandler, R. Sexual Interest and Satisfaction in an Internet Cohort of Patients with Inflammatory Bowel Diseases, Advances in Inflammatory Bowel Disease, Hollywood, Florida, December 2012
45. Zullow, S, Greenberg, D, Tracy, K, Rustgi, A, Cross, RK, and Flasar, MH. A Health Survey of Gastroenterologist Prescribing Practices with Adalimumab for Crohn’s Disease, Advances in Inflammatory Bowel Disease, Hollywood, Florida, December 2012
46. Kugathasan, S, Okou, DT, Mondal, K, Benjamin, AL, Kumar, A, Hussain, SZ, Katz, J, Cross, R, Moulton, DE, Cutler, DJ, and Zwick, ME. Exome Sequencing Identify Novel Variants in African-Americans with Severe Perianal and Colonic Crohn’s Disease, American Gastroenterological Association, Orlando, FL, May 2013
47. Quezada, S, Langenberg, P, and Cross, RK. Cigarette Smoking Adversely Affects Disease Activity and Quality of Life in Patients with Crohn’s Disease Evaluated at Tertiary Referral Center, American Gastroenterological Association, Orlando, FL, May 2013
48. Armbruster, S, Ally, M, Deising, A, Jambaulikar, G, and Cross, RK. The Efficacy and Safety of Endoscopic Balloon Dilation in the Treatment of Stricturing Crohn’s Disease, American College of Gastroenterology. San Diego, CA, November 2013.
49. McLean, L, Chun, J, and Cross, RK. Right Lower Quadrant Pain in a Patient with Ulcerative Colitis, American College of Gastroenterology. San Diego, CA, November 2013.
50. Quezada, S, McDonald, T, Steinbrenner, G, Katzel, L, Goldberg, A, Ryan, A, and Cross, RK. Race is Associated with Fat-Free Body Mass but Not Exercise Fitness in a Tertiary Referral Center IBD Cohort, American College of Gastroenterology. San Diego, CA, November 2013.
51. Hagan, M, Rustgi, A, and Cross, RK. Outcomes of Natalizumab Therapy in Crohn’s Disease: Case Studies from Clinical Practices, Advances in Inflammatory Bowel Disease, Hollywood, Florida, December 2013
52. Osterman, MT, Aberra, F, Cross, R, Liakos, S, McCabe, RP, Shafran, I, Wolf, DC, Hardi, R, Nessel, L, Gilroy, ED, Brensinger, CM, and Lewis, JD. A Randomized Controlled Trial of Mesalamine Dose Escalation for Ulcerative Colitis in Remission, American Gastroenterological Association, Chicago, IL, May 2014
53. Jambaulikar, GD, Armbruster, S, Ally, MR, Deising, A, and Cross, R. Factors Associated with Repeat Endoscopic Balloon Dilation and Surgery After Endoscopic Balloon Dilation for the Treatment of Stricturing Crohn’s Disease, American Gastroenterological Association, Chicago, IL, May 2014
54. Gadani, A, George, L, Jambaulikar, GD, Cross, R, and Ghazi, L. Characteristics and Outcome of Psoriasiform Skin Lesions Caused by Anti-TNF Agents Use for the Treatment of Inflammatory Bowel Disease, American Gastroenterological Association, Chicago, IL, May 2014
55. Jambaulikar, GD, Langenberg, P, Katz, J, Quinn, C, Regueiro, M, Ghazi, L, Patil, SA, Schwartz, DA, Flasar, MH, and Cross, RK. Implementation and Early Results of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD), American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2014.
56. Hagan, M, Jambaulikar, GD, Gadani, A, Christian, K, and Cross, RK. Predictors of Readmission in Hospitalized Patients with Inflammatory Bowel Disease Treated at a Tertiary Care Hospital, American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2014.
57. Hagan, M, Jambaulikar, GD, Osche-Gauvin, K, Schwartz, DA, Higginbotham, T, and Cross, RK. Sexual Function in Patients with Inflammatory Bowel Disease: Results of a Web-Based Health Survey, American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2014.
58. Christian, KE, Jambaulikar, GD, Hagan, M, Brown, S, Gadani, A, Campbell, E, Syed, A, Briscoe, J, and Cross, RK. Predictors of Readmission in Hospitalized Patients with Inflammatory Bowel Disease Treated at a Tertiary Care Hospital, American Gastroenterological Association, Washington, DC, May 2015.
59. Jambaulikar, GD, Lee, J, Aholoukpe, M, Regueiro, M, Schwartz, DA, Ghazi, LJ, Patil, S, Flasar, M, Tracy, K, and Cross, RK. Internal Locus of Control and Increased Self-Efficacy are Associated with Higher Quality of Life in Patients with Inflammatory Bowel Disease, American Gastroenterological Association, Washington, DC, May 2015.
60. Schwartz, DA, Cross, RK, Regueiro, M, Ghazi, L, Swoger, J, Beaulieu, DB, Horst, SN, Flasar, M, Patil, SA, Herline, A, Geiger, T, Muldoon, R, Cone, M, Slaughter, C, and Wise, PE. A Prospective Multicenter Trial Evaluating the Benefit of Initial Seton Placement Prior to Starting Anti-TNF Therapy for the Treatment of Crohn’s Perianal Fistulas, American Gastroenterological Association, Washington, DC, May 2015.
61. Robertson, T, Jambaulikar, G, and Cross, RK. Peripherally inserted central venous catheters are associated with high complication rates in patients with inflammatory bowel disease, American College of Gastroenterology Annual Meeting, Honolulu, HI, October 2015.
62. Latushko, A, Jambaulikar, G, Bafford, AC, Cross, RK, and Ghazi, LJ. Temporary Fecal diversion for perianal and/or colonic Crohn’s disease. American College of Gastroenterology Annual Meeting, Honolulu, HI, October 2015.
63. Rajan, D and Cross, RK. Mycobacterium marinum infection in a patients with Crohn’s disease and a history of pyoderma faciale. Advances in Inflammatory Bowel Disease. Orlando, FL, December 2015.
64. Lee, J, Jambaulikar, G, Bhandari, A, Langenberg, P, Tracy, JK, Quinn, C, and Cross, RK. Implementation and Early Results of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). Mid-Atlantic Telehealth Resource Center Summit, Cambridge, MD, April 2016.
65. Syed, A, Riaz, M, Flasar, MH, and Cross, RK. Early Postoperative Use of Anti-TNF in Patients with Crohn’s Disease is Associated with Decreased Risk of Intra-abdominal Septic and Major Complications After Surgery. American Gastroenterological Association, San Diego, CA, May 2016.
66. Cross, RK, Vekeman, F, Xiao, Y, Wu, E, Chao, J, and Wang, A. Assessment of the Real-world Safety Profile of Vedolizumab Using the United States Food and Drug Administration Adverse Event Reporting System (FAERS). American Gastroenterological Association, San Diego, CA, May 2016.
67. Cross, RK, Kornak, J, Burton, A, and Zubrow, MT. Implementation of Telehealth Visits in a Tertiary Referral Center. American College of Gastroenterology Annual Meeting, Las Vegas, NV, October 2016.
68. Dubinksy, MC, Cross, R, Sandborn, WJ, Long, M, Eichner, S, and Wang, A. The Incidence of Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease Treated with Vedolizumab and Anti-TNF Therapies. Advances in Inflammatory Bowel Disease. Orlando, FL, December 2016.
69. Perinbasekar, RA, Brown, SA, Syed, N, Lonsako, S, and Cross, RK. Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Drug and Anti-Drug Antibody Concentration Utilizing the LabCorp Assay in Inflammatory Bowel Disease (IBD) Patients. American Gastroenterological Association, Chicago, IL, May 2017.
70. Perinbasekar, RA, Brown, SA, Syed, N, Lonsako, S, and Cross, RK. Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Drug and Anti-Drug Antibody Concentration Utilizing the LabCorp Assay in Inflammatory Bowel Disease (IBD) Patients. 12th UVa Annual Conference of Liver Disease & Gastroenterology, Charlottesville, VA, June 2017.
71. Long, MD, Cross, R, Saha, S, Afzali, A, Higgins, P, Martin, CF, and Herfarth, HH. Autoimmune Paradoxical Reactions in Inflammatory Bowel Diseases Longitudinal (APRIL) Cohort: Methodology and Initial Results. American Gastroenterological Association, Chicago, IL, May 2017.
72. Cross, RK, Osterman, MT, Panaccione, R, Afzali, A, Song, X, Shi, N, Ding, Y, and Wang, A. The Incidence of Cardiovascular Events in Patients with Crohn’s Disease Treated with Vedolizumab and Anti-TNF Therapies. American Gastroenterological Association, Chicago, IL, May 2017.
73. Chudy-Onwugaje, K, Mamunes, A, and Cross, R. Predictors of Increased Utilization of Healthcare Resources in Patients with Inflammatory Bowel Disease. American Gastroenterological Association, Chicago, IL, May 2017.
74. Cross, RK, Barr, E, and Rajan, D. Infliximab Is Not Associated with Excess Weight Gain in Women: An Analysis of Clinical Trial Data from ACCENT I, ACCENT II, ACT 1, and SONIC. American Gastroenterological Association, Chicago, IL, May 2017.
75. Cross, RK, Quinn, C, Russman, K, Regueiro, M, Ghazi, L, Schwartz, DA, Patil, SA, Quezada, SM, Horst, S, Beaulieu, D, Tracy, JK, Jambaulikar, G, and Langenberg, P. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD). American Gastroenterological Association, Chicago, IL, May 2017.
76. Ballengee, CR, Prince, J, Baldassano, RN, Denson, LA, Katz, J, Cross, RK, Patel, AS, Quiros, A, Tomer, G, and Kugathasan, S. Procollagen III N-Terminal Propeptide (PIIINP) as a Circulating Biomarker for Active Stricture Development in Pediatric Crohn’s Disease. American Gastroenterological Association, Chicago, IL, May 2017.
77. Perinbasekar, RA, Brown, SA, Syed, N, Lonasko, S and Cross, RK. Proactive Monitoring of Infliximab (IFX) and Adalimumab (ADA) Using LabCorp’s Electrochemiluminescence Assay (ECLIA) in Inflammatory Bowel Disease Patients. American College of Gastroenterology Annual Meeting, Orlando, FL, October 2017.
78. Almario, JA, Yfantis, H, Cross, R, and Urrunaga, N. Lipohyperplasia of the Terminal Ileum Causing Obstructive Symptoms in a Patient with Biopsy Proven Crohn’s Disease. American College of Gastroenterology Annual Meeting, Orlando, FL, October 2017.
79. Abutaleb, A, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Ghazi, L, Patil, S, Quezada, SM, Russman, K, Quinn, CC, and Cross, RK. Delivery of Weekly Educational Text Messages to Patients with Inflammatory Bowel Disease Through a Telemedicine System Improves Their Disease-Specific Knowledge Over 1 Year. American College of Gastroenterology Annual Meeting, Orlando, FL, October 2017.
80. Chudy-Onwugaje, K, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Katz, J, Ghazi, L, Patil, S, Quezada, S, Russman, K, Quinn, C, and Cross, RK. Demographic and Clinical Predictors of Adherence to Self-Testing in Telemedicine for Patients with Inflammatory Bowel Disease. American College of Gastroenterology Annual Meeting, Orlando, FL, October 2017.
81. Chiorean, M, Afzali, A, Cross, RK, Zhou, Z, Macaulay, D, Ganguli, A, and Wang, A. Patient Outcomes and Economic Impact of Switching from Anti-TNF Therapy to Adalimumab, Infliximab, or other Anti-TNF Compared with Switching from Anti-TNF Therapy to Vedolizumab. Crohn’s & Colitis Congress, Las Vegas, NV, January 2018.
82. Sivasailam, B, Ghazi, L, Patil, SA, Quezada, SM, Russman, K, Riaz, M, Jambaulikar, G, Quinn, CC, Langenberg, P, Tracy, JK, Collins, JF, Regueiro, M, Schwartz, DA, Katz, J, and Cross, RK. Telemedicine for Patients with Inflammatory Bowel Disease (TELE-IBD) Decreases Inflammatory Bowel Disease (IBD) Related Hospitalizations. Crohn’s & Colitis Congress, Las Vegas, NV, January 2018.
83. Cross, RK, Langenberg, P, Regueiro, M, Schwartz, DA, Tracy, JK, Collins, J, Katz, J, Ghazi, L, Patil, S, Quezada, SM, Russman, KM, Riaz, M, Jambaulikar, G, Sivasailam, B, and Quinn, CC. A randomized controlled trial of TELEmedicine for patients with inflammatory bowel disease (TELE-IBD). American Gastroenterological Association, Washington, DC, June 2018.
84. Chudy-Onwugaje, K, Mamunes, A, Schwartz, D, Horst, S, Beaulieu, D, Dalal, R, Scoville, E, Adams, D, Wiley, J, Motley, A, and Cross, R. Predictors of excess healthcare utilization in patients with inflammatory bowel disease. American Gastroenterological Association, Washington, DC, June 2018.
85. Chudy-Onwugaje, K, Abutaleb, A, Langenberg, P, Regueiro, M, Schwartz, DA, J, Tracy, JK, Katz, J, Ghazi, L, Patil, S, Quezada, S, Russman, K, Quinn, C, Cross, R. Age modifies the association between depressive symptoms and adherence to self-testing with telemedicine in patients with inflammatory bowel disease. American Gastroenterological Association, Washington, DC, June 2018.
86. Roth, E, Chard, S, Eckert, K, and Cross, R. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): A Qualitative Assessment. American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2018.
87. Cross, R, Ahmed, T, Chasen, R, Cheifetz, A, Higgins, PDR, Leighton, JA, Scherl, E, Swaminath, A, Simone, LC, Greene, L, and Sapir, T. Perceptions of Shared Management and Primary Care Competencies in Inflammatory Bowel Disease (IBD) Care Informed Through a Gastroenterologist-Led Mentorship Model. American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2018.
88. Syed, N, Brown, S, Perinbasekar, R, Wentz, A, and Cross, R. Association of Higher Infliximab Drug Levels with Response Rates of Perianal Crohn’s Disease. American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2018.
89. Syed, N, Christian, KE, Kelly, S, Wentz, A, and Cross, R. Intensified Infliximab Dosing in Acute Severe Ulcerative Colitis. American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2018.
90. Rubin, J, Christian, KE, Wong, U, Cross, R, Bafford, A, and Patil, S. Case of Invasive Metastatic Breast Cancer Mimicking Crohn’s Disease. American College of Gastroenterology Annual Meeting, Philadelphia, PA, October 2018.
91. Chiorean, M, Afzali, A, Cross, R, Zhou, Z, Macaulay, D, Ganguli, A, and Wang, A. Economic Impact of Switching from Anti-TNF Therapy to Adalimumab, Infiximab or other Anti-TNF Compared with Switching from Anti-TNF Therapy to Vedolizumab. 2019 Crohn’s and Colitis Congress, Las Vegas, NV, February 2019.
92. Schleip, M, Chudy-Onwugaje, K, Langenberg, P, Regueiro, M, Schwartz, D, Tracy, K, Ghazi, L, Patil, S, Quezada, S, Russman, K, Horst, S, Beaulieu, D, Quinn, C, Jambaulikar, G, and Cross, R. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Studying Quality of Life with the Short Form 12. 2019 Crohn’s and Colitis Congress, Las Vegas, NV, February 2019.
93. Cross, R, Scherl, E, Weinbaum, E, Greene, L, Eichenbrenner, P, Fraser, K, Bender, AS, and Moreo, K. Tethered IBD Tools to Support Patients and Providers in Shared Decision-Making and Therapy Access. 2019 Crohn’s and Colitis Congress, Las Vegas, NV, February 2019.
94. Ghosh, S, Aberra, F, Cross, R, Zhou, W, Chen, N, Lee, WJ, and Panaccione, R. Effect of upadacitinib on patient-reported symptoms by the new ulcerative colitis symptoms questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the phase 2b study U-ACHIEVE. 14th Congress of ECCO. Copenhagen, Denmark, March 2019.
95. Bilgrami, Z, Abutaleb, A, Chudy-Onwugaje, K, Quinn, C, Russman, K, Regueiro, M, Ghazi, L, Schwartz, DA, Patil, SA, Quezada, SM, Horst, S, Beaulieu, D, Tracy, JK, Jambaulikar, G, Langenberg, P and Cross, RK. Effect of TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD) on Patient Activation and Self-Efficacy. American Gastroenterological Association, San Diego, CA, May 2019.
96. Schleip, M, Chudy-Onwugaje, K, Langenberg, P, Regueiro, M, Schwartz, D, Tracy, K, Ghazi, L, Patil, S, Quezada, S, Russman, K, Horst, S, Beaulieu, D, Quinn, C, Jambaulikar, G, and Cross, R. TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD): Studying Quality of Life with the Short Form 12. American Gastroenterological Association, San Diego, CA, May 2019.
97. Cohen, BL, Fleshner, P, Kane, SV, Herfarth, HH, Palekar, N, Farraye, FA, Leighton, JA, Katz, J, Cohen, RK, Gerich, ME, Cross, RK, Higgins, PDR, Tinsley, A, Glover, SC, Siegel, CA, Bohl, JL, Iskander, H, Raymond, S, Huang, R, Suarez-Farinas, M, and Sands, BE. Prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for post-operative infection (PUCCINI). American Gastroenterological Association, San Diego, CA, May 2019.
98. Sivasailam, B, Manski, S, Wentz, A, and Cross, RK. Presence of obstructive symptoms and perianal Crohn’s disease is predictive of surgery after endoscopic balloon dilation. American College of Gastroenterology, San Antonio, TX, October 2019.
99. Feldman, H, George, L, Hine, A, Zullow, S, Hudesman, D, and Cross, RK. Mild endoscopic activity is associated with an increased risk of relapse in patients with ulcerative colitis. American College of Gastroenterology, San Antonio, TX, October 2019.
100. Graziano, E, Gheysens, K, Campbell, J, Cross, R, and Vaughn, B. Clinical outcomes following therapeutic drug monitoring of vedolizumab in inflammatory bowel disease. American College of Gastroenterology, San Antonio, TX, October 2019.
101. Kamal, N, Motwani, K, Wellington, J, Wong, U, and Cross, RK. Fecal incontinence in inflammatory bowel disease. American Gastroenterological Association, Chicago, IL, May 2020.
102. Hudesman, D, Horst, SN, Zhuo, J, Mackey, R, Harrison, RW, Crabtree, MM, Emeanuru, K, Ahmad, H, Nguyen, J, Sauk, J, and Cross, RK. Considerable work productivity loss in patients with inflammatory bowel disease whether disease is active or in clinical remission. .American Gastroenterological Association, Chicago, IL, May 2020.
103. Horst, SN, Hudesman, D, Zhuo, J, Harrison, RW, Mackey, R, Crabtree, MM, Emeanuru, K, Ahmad, H, Nguyen, J, Sauk, J, and Cross, RK. Poor patient-reported outcomes were observed in patients in the Corrona inflammatory bowel disease registry, despite being in clinical remission. American Gastroenterological Association, Chicago, IL, May 2020.
104. Causey, E, George, L, Rossman, L, Shah, NB, Zuckerman, A, Slaughter, J, Duley, C, Annis, K, Wagnon, J, Dalal, R, Scoville, E, Beaulieu, DB, Schwartz, D, Cross, RK, and Horst, SN. Risk factors for non-adherence to self-injectable biologic therapy in inflammatory bowel disease: A validation cohort study. American Gastroenterological Association, Chicago, IL, May 2020.
105. George, LA, Feldman, HT, Abutaleb, A, Hine, A, Zullow, S, Hudesman, D, Axelrad, J, and Cross, RK. Histologic inflammation defined by the Robarts Histopathologic Index may predict future clinical relapse in ulcerative colitis patients in endoscopic remission. American Gastroenterological Association, Chicago, IL, May 2020.
106. Cross, RK, Naegeli, AN, Harrison, RW, Moore, PC, Mackey, RH, Lemay, CA, Dong, Y, Arora, V, Morris, N, Malatestinic, WN, Kayhan, C, and Korzenik, J. Disease burden and patient-reported outcome measures among ulcerative colitis patients according to therapy at enrollment into the Corrona IBD Registry. American Gastroenterological Association, Chicago, IL, May 2020.
107. Sauk, J, Cross, RK, Abraham, BP, Horst, SN, Hudesman, D, Kochlar, G, Stidham, RW, Wolf, DC, Harrison, RW, Mackey, RH, and Korzenik, J. Characteristics, disease burden, and patient-reported outcome measures among inflammatory bowel disease patients by insurance coverage at enrollment into the Corrona IBD Registry. American Gastroenterological Association, Chicago, IL, May 2020.
108. Saha, S, Caldera, F, Bohm, M, Fischer, M, Sagi, SV, Kaur, M, Shukla, R, Snapper, SB, Korzenik, JR, Perera, LP, Yarur, AJ, Cross, RK, Wong, U, Pekow, J, Dalal, S, Higgins, PDR, Bishu, S, Reynolds, G, Ciorba, M, Deepak, P, Scoville, EA, Wilson, KT, Hudesman, D, Loke, P, Dassopoulos, T, Wells, K, Norris, C, Duerr, RH, Bewtra, M, Raffals, L and Lewis, J. Creation of a prospective, longitudinal adult inflammatory bowel disease cohort combining high-resolution phenotyping with biosample collection to facilitate precision medicine-SPARC IBD. American Gastroenterological Association, Chicago, IL, May 2020.
109. Syed, N, Tolaymat, M, Brown, SA, Sivasailam, B, and Cross, RK. Proactive drug monitoring is associated with higher persistence to infliximab and adalimumab treatment and lower healthcare utilization compared to reactive and clinical monitoring. American Gastroenterological Association, Chicago, IL, May 2020.
110. Chudy-Onwugaje, K, Ali, O, Gheysens, K, Motwani, K, Jackson, R, Kim, GE and Cross, RK. Prevalence and predictors of early-onset colorectal neoplasms in average-risk young adults. American Gastroenterological Association, Chicago, IL, May 2020.
111. Ritaccio, G, Stoleru, G, Abutaleb, A, Cross, RK, Shetty, K, Sakiani, S, and Wong, U. Non-alcoholic fatty liver disease prevalence and progression of fibrosis in a cohort of patients with inflammatory bowel disease. American Gastroenterological Association, Chicago, IL, May 2020.
112. Chudy-Onwugaje, K, Gheysens, K, Motwani, K, Kim, GE, Jackson, R, Ali, O, Akhmedzhanov, F, and Cross, RK. Sex differences in the association between obesity and colorectal adenoma in average-risk adults under 50 in the United States. American Gastroenterological Association, Chicago, IL, May 2020.
113.
Brief Communications
1. Cross, RK. Phone calls offer ‘early warning’ in IBD. GI & Hepatology News 2014;8(6):7.
2. Cross, RK. Telemanagement for Inflammatory Bowel Disease. Gastroenterology & Hepatology. 2014;10(4):255-257.
3. Cross, RK. Less than 20% report serious disability 13 years after IBD diagnosis. GI & Hepatology News. 2014;8(8):14.
4. Cross, RK. TOUCHSTONE: Ozanimod shows promise as induction, maintenance therapy for UC. Healio Gastroenterology. 2016;
5. Cross, RK. Monitoring dysplasia and cancer in patients with chronic colitis. Audio Digest. 2019 Aug 7;33(15).
Major Invited Speeches
1. Holy Cross Hospital, Medical Grand Rounds, January 11, 2005, “Overview of Inflammatory Bowel Disease”
2. Good Samaritan Hospital, Medical Grand Rounds, April 27, 2005, “Overview of Inflammatory Bowel Disease”
3. Laurel Regional Hospital, Medical Grand Rounds, May 2, 2005, “Overview of Inflammatory Bowel Disease”
4. Northwest Hospital, Medical Grand Rounds, June 1, 2005, “Overview of Inflammatory Bowel Disease”
5. Mariners Institute, 2005 Women’s Health Symposium, November 4, 2005, “An Update on Gastrointestinal Issues in Women’s Health”
6. Harbor Hospital, Medical Grand Rounds, November 11, 2005, “Overview of Inflammatory Bowel Disease”
7. Frederick Memorial Hospital, Medical Grand Rounds, January 20, 2006, “Overview of Inflammatory Bowel Disease”
8. Good Samaritan Hospital, Medical Grand Rounds, April 12, 2006, “Ulcerative Colitis”
9. Mercy Hospital, Medical Grand Rounds, May 10, 2006, “Overview of Inflammatory Bowel Disease”
10. University of Maryland 6th Annual Internal Medicine Update, June 13, 2006, “Crohn’s Disease”
11. St. Agnes Hospital, Medical Grand Rounds, October 19, 2006, “Overview of Inflammatory Bowel Disease”
12. Union Memorial Hospital, Medical Grand Rounds, December 21, 2006, “Updates in Inflammatory Bowel Disease”
13. Medical College of Wisconsin, IBD Working Group, January 4, 2007, “Optimizing Outcomes in Patients with Inflammatory Bowel Disease”
14. Vanderbilt University, GI Grand Rounds, February 2, 2007, “Optimizing Outcomes in Patients with Inflammatory Bowel Disease”
15. AGA Institute, AGA CME Café, March 2007, “Effective Management of Ulcerative Colitis”
16. Mt. Sinai Inflammatory Bowel Disease Grand Rounds, July 2007, “Optimizing Outcomes in Patients with Inflammatory Bowel Disease”
17. Georgetown University Medical Grand Rounds, February 2008, “Women’s Health Issues in Inflammatory Bowel Disease”
18. Mercy Medical Center Medical Grand Rounds, April 2008, “ABC’s of Inflammatory Bowel Disease”
19. American College of Physicians, Delaware Chapter, Annual Meeting, September 2008, “Overview of Inflammatory Bowel Disease”
20. CCFA Maryland/Delaware Chapter Patient Education Day, November 2008, “Updates in Diagnostic Studies in Inflammatory Bowel Disease”
21. University of Pittsburgh Inflammatory Bowel Disease Grand Rounds, March 2009, “Biologics in IBD: Anti-TNF and Beyond”
22. St. Agnes Medical Grand Rounds, March 2009, “Overview of Inflammatory Bowel Disease”
23. Foundation for Clinical Research in IBD, April 2009, “Advances in IBD 2009 -New and Current Treatment”
24. Pennsylvania Society of Gastroenterology Annual Meeting, October 2009, “What’s New in Biologic Therapy for Inflammatory Bowel Disease”
25. Mt. Sinai Inflammatory Bowel Disease Grand Rounds, November 2009, “Optimizing Outcomes in Patients with Inflammatory Bowel Disease”
26. Tennessee Physician Advisory Committee, February 2010, “What’s New in Biologic Therapy for Inflammatory Bowel Disease”
27. Baltimore Gut Club, March 2010, “What’s New in Biologic Therapy for Inflammatory Bowel Disease”
28. Mid-West Regional Academic Inflammatory Bowel Disease Centers, April 2010, “Academic IBD Center-Money Pit or Profitable?”
29. Foundation for Clinical Research in IBD, May 2010, Advances in IBD 2010, Indianapolis, IN
30. Good Samaritan Hospital, Medical Grand Rounds, August 2010, “Crohn’s Disease: Diagnosis, Treatment, and Complications”
31. Walter Reed Army Medical Center, October 2010, “IBD Roundtables”
32. Washington Hospital Center, January 2011, “IBD Roundtables”
33. National Capital Consortium, April 2011,” IBD Roundtables”
34. Georgetown University, May 2011, “IBD Roundtables”
35. The AGA Institute, Focused Clinical Update, May 2011, “Emerging Therapies in IBD”
36. University of Oklahoma Medical Center, September 2011, “Resource Needs and Revenue Streams in an Academic IBD Practice”.
37. University of Oklahoma Medical Center, September 2011, “IBD Roundtables”
38. American College of Gastroenterology Annual Meeting, October 2011, “Mucosal Healing or Clinical Endpoints-Which is Best?”
39. Foundation for Clinical Research in IBD, November 2011, “Advances in IBD 2011”, Des Moines, IA.
40. Advances in Inflammatory Bowel Disease, December 2011, “Extraintestinal Manifestations of IBD”, Hollywood, FL
41. Walter Reed Army Medical Center, January 2012, “IBD Roundtables”
42. Cooper University, February 2012, “IBD Roundtables”
43. Louisiana State University Health Sciences Center, March 2012, “Resource Needs and Revenue Streams in an Academic IBD Practice”.
44. Baystate Medical Center/Tufts University School of Medicine, March 2012, “IBD Roundtables”
45. St. Agnes Medical Grand Rounds, April 2012, “Overview of IBD Therapy”
46. American Gastroenterological Association Digestive Diseases Week, May 2012, “Multidisciplinary Management of Complicated Crohn’s Disease”
47. American College of Gastroenterology Regional Postgraduate Course, September 2012, “Maximizing the First IBD Visit and Optimizing Care”.
48. Walter Reed Army Medical Center, September 2012, “IBD Roundtables”.
49. University of Michigan, September 2012, Resource Needs and Revenue Streams in an Academic IBD Practice”.
50. University of Michigan, September 2012, “Telemedicine in Inflammatory Bowel Disease”.
51. Advances in Inflammatory Bowel Disease, December 2012, “Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD”, Hollywood, FL
52. Advances in Inflammatory Bowel Disease, December 2012, “Antibiotics and Corticosteroids: Indications and Optimizing Therapy”, Hollywood, FL
53. American Gastroenterological Association Digestive Diseases Week, May 2013, “IBD: Perioperative Prevention”, Orlando, FL
54. 5th Update in IBD, September 2013, “Telemedicine in IBD-is this the future and how can I implement in my practice?”, Chapel Hill, NC
55. 5th Annual Consensus and Controversies in Gastroenterology and Hepatology, “Advanced Techniques for Dysplasia Detection in IBD”, Baltimore, MD
56. Capital Gastroenterology Journal Club, October 2013, “IBD Roundtables”, Washington, DC
57. American College of Surgeons 2013 Clinical Congress, October 2013, “Biologics and Surgery”, Washington, DC
58. Advances in Inflammatory Bowel Disease, December 2013, “How to Assess and Manage Strictures, Abscesses, and Phlegmons in the Complicated Crohn’s Disease Patient”, Hollywood, FL
59. Geisinger Medical Center Medical Grand Rounds, January 2014, “How to Recognize and Manage Emergencies in IBD”, Danbury, PA
60. Geisinger Medical Center, March 2014, “IBD Roundtables”, Danbury, PA.
61. American Gastroenterological Association Digestive Diseases Week, May 2014, “Telemanagement of IBD”, Chicago, IL
62. IBD 2020 USA Meeting, May 2014, “Can telemedicine be used for IBD care?”, New Orleans, LA.
63. Maryland Academy of Family Physicians, June 2014, “Biologic Therapies in IBD”, Frederick, MD
64. Mastering Clinical Challenges and Emerging Therapies in IBD: Individualizing our Approach to IBD, July 2014, “Prognostication in IBD: Can we really predict the future or are we just describing the past?”, Chicago, IL.
65. Gastrointestinal Health Foundation, July 2014, “Managing Iron Deficiency Anemia in GI Disorders”, Bethesda, MD
66. Mercy Medical Center, September 2014, “Crohn’s Refractory to Treatment”, Baltimore, MD
67. Gastrointestinal Health Foundation, September 2014, “IBD Alliance Program 2014”, Columbia, MD
68. Walter Reed Army Medical Center, September 2014, “IBD Roundtables”, Bethesda, MD.
69. Gastrointestinal Health Foundation, September 2014, “IBD Alliance Program 2014”, Columbia, MD
70. Crohn’s and Colitis Foundation of America, October 2014, “Crohn’s Disease”.
71. Gastrointestinal Health Foundation, October 2014, “IBD Alliance Program 2014”, Bethesda, MD
72. George Washington University, November 2014, “IBD Roundtables”, Washington, DC.
73. Advances in Inflammatory Bowel Disease, December 2014, “5-ASA Products and Corticosteroids: Indications and Approaches ”, Orlando, FL
74. Advances in Inflammatory Bowel Disease, December 2014, “Sexual Dysfunction in IBD: Case Studies ”, Orlando, FL
75. Advances in Inflammatory Bowel Disease, December 2014, “A Patient-Centered Approach to Achieve Safety and Efficacy in the Long-Term Management of Ulcerative Colitis”, Orlando, FL
76. Gastrointestinal Health Foundation, January 2015, “IBD Alliance Program 2014”, Bethesda, MD
77. Gastrointestinal Health Foundation, January 2015, “IBD Alliance Program 2014”, Columbia, MD
78. Crohn’s and Colitis Foundation of America 2015 Patient Education Program, March 2015, “Updates in Medications and Treatment for Crohn’s and Colitis”, Atlanta, GA
79. Crohn’s and Colitis Foundation of America Updates in Inflammatory Bowel Disease 2015, March 2015, “Evolving Therapies: Current Trends and Beyond”, Atlanta, GA
80. The Ninth Penn Inflammatory Bowel Disease Symposium, March 2015, “Mesalamine-What’s New in 2015?”, Philadelphia, PA
81. The Ninth Penn Inflammatory Bowel Disease Symposium, March 2015, “Combination Therapy-For Whom and What Regimen?”, Philadelphia, PA
82. Institute for Digestive Health and Liver Diseases at Mercy, April 2015, “IBD Roundtables”, Baltimore, MD
83. Pennsylvania State University Hershey Medical Center, April 2015, “IBD Roundtables”, Hershey, PA
84. American Gastroenterological Association Digestive Diseases Week, May 2015, “If It’s Going to Be Like This, I’m Leaving for Private Practice!-Academicians Navigating the Move to RVU-Based Compensation, Washington, DC
85. Innovation Challenges and Biosimilar Considerations for Gastroenterology, May 2015, “Considerations for Interchangeability and Substitution”, Washington, DC
86. Pennsylvania State University Hershey Medical Center, April 2015, “Telemedicine in Patients with Inflammatory Bowel Disease”, Hershey, PA
87. North American Center for Continuing Medical Education, June 2015, “Emerging Paradigms in the Management of Crohn’s Disease”, Philadelphia, PA
88. North American Center for Continuing Medical Education, June 2015, “Emerging Paradigms in the Management of Crohn’s Disease”, Parsippany, NJ
89. GI Health Foundation, July 2015, “Advances in Managing Iron Deficiency Anemia in IBD”, Baltimore, MD
90. North American Center for Continuing Medical Education, August 2015, “Emerging Paradigms in the Management of Crohn’s Disease”, Boston, MA
91. North American Center for Continuing Medical Education, June 2015, “Emerging Paradigms in the Management of Crohn’s Disease”, New York, NY
92. Auberge Saint-Antoine, September 2015, “Telemedicine for Inflammatory Bowel Disease”, Quebec City, Quebec.
93. Hospital Pierre-Boucher, September 2015, “Telemedicine for Inflammatory Bowel Disease”, Longueuil, Quebec.
94. Ottawa Gut Club, September 2015, “Telemedicine for Inflammatory Bowel Disease”, Ottawa.
95. Montreal General Hospital, September 2015, “Telemedicine for Inflammatory Bowel Disease”, Montreal, Quebec.
96. Hospital Maisonneuve-Rosemont, September 2015, “Telemedicine for Inflammatory Bowel Disease”, Montreal, Quebec.
97. Gastrointestinal Health Foundation, October 2015, “Advances in Managing Iron Deficiency Anemia”, Bethesda, MD.
98. American College of Gastroenterology Post Graduate Course, October 2015, “Personalized Medicine in IBD”, Honolulu, HI.
99. Prime, Inc., October 2015, “Optimizing IBD Quality of Care & Treatment Outcomes for Team-Based Competencies”, Honolulu, HI.
100. Allegheny General Hospital, November 2015, “Personalized Approaches to Sustained Biologic Remission in Crohn’s Disease”, Pittsburgh, PA.
101. Allegheny General Hospital, November 2015, “Optimizing Biologic Therapy in Patients with IBD”, Pittsburgh, PA.
102. Advances in Inflammatory Bowel Disease, December 2015, “Challenges in the Management of IBD in Elderly Patients”, Orlando, FL.
103. Advances in Inflammatory Bowel Disease, December 2015, “Recognizing and Managing Side Effects and Complications Due to Medications Used to Treat IBD: Case-Studies”, Orlando, FL.
104. Mt. Sinai Hospital, February 2016, “Telemedicine for Inflammatory Bowel Disease”, Toronto, ON.
105. Kensington Clinic Journal Club, February 2016, “IBD Roundtable”, Toronto, ON
106. North Bay Gastroenterology, February 2016, “Telemedicine for Inflammatory Bowel Disease”, North Bay, ON.
107. Gastrointestinal Health Foundation, February 2016, “IBD Alliance Program 2016”, Baltimore, MD.
108. Focus on Complex Inflammatory Bowel Disease, NYU School of Medicine, March 2016, “Management of Dysplasia in IBD: Review of SCENIC Guidelines”, New York, NY.
109. Focus on Complex Inflammatory Bowel Disease, NYU School of Medicine, March 2016, “Prevention of Postoperative Recurrence in Crohn’s Disease”, New York, NY.
110. 26th Annual Digestive Disease National Coalition Public Policy Forum and Institutional Member Forum, March 2016, “Emerging Medications in IBD”, Washington, DC.
111. Gastrointestinal Health Foundation, April 2016, “IBD Alliance Program 2016”, Lancaster, PA.
112. 2nd Annual Clinical Updates in Inflammatory Bowel Disease, Florida Hospital Medical Center, April 2016, “State of the Art-Positioning Biologics in the Medical Management of Crohn’s Disease”, Orlando, FL.
113. 2nd Annual Clinical Updates in Inflammatory Bowel Disease, Florida Hospital Medical Center, April 2016, “Management of IBD in Women-Preconception to Peripartum Management of Patients with IBD”, Orlando, FL.
114. Gastrointestinal Health Foundation, April 2016, “IBD Alliance Program 2016”, Baltimore, MD.
115. Medical Grand Rounds, St. Agnes Hospital, “Current Management of IBD”, April 2016, Baltimore, MD.
116. Gastrointestinal Health Foundation, April 2016, “IBD Alliance Program 2016”, Lancaster, PA.
117. Prime Education, Inc., June 2016, “Payer and Provider Discussions to Overcome Barriers in Evidence-Based Treatment Decisions in HCV & IBD”, Baltimore, MD.
118. American College of Gastroenterology Eastern Regional Course, June 2016, Systemic Complications in IBD Patients”, Washington, DC.
119. Mercy Medical Center Best of DDW/EASL, June 2016, “Best of DDW 2016 IBD Therapeutics”, Baltimore, MD.
120. Mastering Clinical Challenges and Emerging Therapies in IBD, July 2016, “Healing the Bowel: How to Do It, How to Know You’ve Got It”, Chicago, IL.
121. Mastering Clinical Challenges and Emerging Therapies in IBD, July 2016, “Case Discussion: Refractory Proctitis, Novel Approaches for a Difficult Problem”, Chicago, IL.
122. Lehigh Valley Hospital-Cedar Crest Grand Rounds, July 2016, “Personalized Approaches to Sustained Biologic Remission in Crohn’s Disease”, Allentown, PA.
123. GI Consultants, LLC, August 2016, “IBD Roundtables”, Dover, DE.
124. Westglen GI Consultants, September 2016, “IBD Roundtables”, Kansas City, MO.
125. Florida Gastroenterologic Society, September 2016, “Challenging Cases in IBD”, Orlando, FL.
126. North American Center for Continuing Medical Education, November 2016, “Advancing IBD Practice in Our Communities: A Focus on Evidence-based Care”, New York, NY.
127. North American Center for Continuing Medical Education, December 2016, “Advancing IBD Practice in Our Communities: A Focus on Evidence-based Care”, Chicago, IL.
128. Advances in Inflammatory Bowel Disease, December 2016, “Neurologic, Rheumatologic, and Optic Complications Related to Immunomodulators and Biologics”, Orlando, FL.
129. Advances in Inflammatory Bowel Disease, December 2016, “The Endoscopic Management of Strictures in Crohn’s Disease”, Orlando, FL.
130. Advances in Inflammatory Bowel Disease, December 2016, “What to Do When a Complication Due to IBD Therapy Occurs?”, Orlando, FL.
131. Advances in Inflammatory Bowel Disease, December 2016, “Sexual Dysfunction in Male and Female IBD Patients: Case Studies”, Orlando, FL.
132. North American Center for Continuing Medical Education, January 2017, “Advancing IBD Practice in Our Communities: A Focus on Evidence-based Care”, Houston, TX.
133. South Dakota Academy of Family Physicians, February 2017, “Coordinating Care in IBD: Diagnosis and Co-Management Strategies for Family Physicians”, Deadwood, SD.
134. IBDSF Models of Psychosocial Care Integration, February 2017, “Review of Relevance of Psychosocial Care”, Los Angeles, CA.
135. Genesys Regional Medical Center, March 2017, “IBD Roundtables”, Flint, MI.
136. Walter Reed Medical Center, April 2017, “IBD Roundtables”, Bethesda, MD.
137. Florida Hospital, April 2017, “State of the Art-Positioning Biologics in the Management of Crohn’s Disease”, Orlando, FL.
138. Florida Hospital, April 2017, “Positioning of Newly Released and Future Therapies in Management of IBD”, Orlando, FL.
139. Lennox Hill Hospital, May 2017, “Telemedicine in Patients with Inflammatory Bowel Disease”, New York, NY.
140. American Gastroenterological Association Digestive Diseases Week, May 2017, “Ethical Pitfalls of Telemedicine”, Chicago, IL.
141. Gastrointestinal Health Foundation, June 2017, “IBD Alliance Program 2017”, Richmond, VA.
142. Gastrointestinal Health Foundation, July 2017, “IBD Alliance Program 2017”, Bethesda, MD.
143. Gastrointestinal Health Foundation, September 2017, “IBD Alliance Program 2017”, Bethesda, MD.
144. Gastrointestinal Health Foundation, October 2017, “IBD Alliance Program 2017”, Richmond, VA.
145. Virginia Commonwealth University GI Grand Rounds, October 2017, “Healing the Bowel: Is It Needed and How Do You Do It?”, Richmond, VA
146. Hunter Holmes McGuire VA Medical Center Medical Grand Rounds, October 2017, “Telemedicine for Patients with Inflammatory Bowel Disease”, Richmond, VA
147. Advances in Inflammatory Bowel Disease, November 2017, “Advances in IT that Will Improve Patient Care: Telemedicine and Remote Telemedicine”, Orlando, FL
148. Advances in Inflammatory Bowel Disease, November 2017, “Sexual Dysfunction in IBD: Case Studies”, Orlando, FL
149. Advances in Inflammatory Bowel Disease, November 2017, “Use of Therapeutic Endoscopic Techniques to Manage Complications of Crohn’s Disease”, Orlando, FL
150. Crohn’s and Colitis Foundation Patient Education Day, November 2017, “What’s on the Horizon: New & Emerging Treatment”, Towson, MD
151. Johns Hopkins Medicine Emerging Treatments & Practice Patterns for Inflammatory Bowel Diseased, November 2017, “Telemedicine for Patients with Inflammatory Bowel Disease, Baltimore, MD
152. Atlantic Health Gastroenterology, December 2017, “IBD Roundtables”, Morristown, NJ
153. American College of Gastroenterology IBD School, January 2018, “Goals of Caring for the IBD Patient”, Las Vegas, NV
154. American College of Gastroenterology IBD School, January 2018, “Drug and Disease Monitoring”, Las Vegas, NV
155. 2018 American College of Gastroenterology Board of Governors/American Society for Gastrointestinal Endoscopy Best Practices Course, January 2018, “Telemedicine Opportunities for the GI Practice”, Las Vegas, NV.
156. ACG/LGS Regional Postgraduate Course, March 2018, “Telemedicine”, New Orleans, LA.
157. Prime, March 2018, “Hear the Latest Evidence to Improve IBD Care in Your Home Town”, Frederick, MD.
158. University of North Carolina GI Grand Rounds, April 2018, “Telemedicine for Patients with Inflammatory Bowel Disease”, Chapel Hill, NC.
159. Fourth Annual Orlando Clinical Updates in Inflammatory Bowel Disease, April 2018, “Optimizing the use of anti-TNFs in the Management of Moderate to Severe Inflammatory Bowel Disease”, Orlando, FL.
160. Fourth Annual Orlando Clinical Updates in Inflammatory Bowel Disease, April 2018, “Management of IBD in women: Preconception to Peripartum Management of Patients with IBD”, Orlando, FL.
161. Walter Reed Medical Center, May 2018, “IBD Roundtables”, Bethesda, MD.
162. Mastering Clinical Challenges and Emerging Therapies in IBD, “The moderate to severe CD patient: What are the options and where do new therapies including biosimilars fit in the picture?”, July 2018, Chicago, IL.
163. Prime, “IBD in the Era of Targeted Treatment: Navigating the Therapy Pipeline”, June 2018, Baltimore, MD.
164. GO GI Outlook 2018: the Practice Management Conference, “Telemedicine Onward and Upward”, August 2018, Austin, Tx.
165. New Advances in Inflammatory Bowel Disease, “Strategies for Monitoring Dysplasia”, September 2018, San Diego, CA.
166. New Advances in Inflammatory Bowel Disease, “IBD through the Ages”, September 2018, San Diego, CA.
167. Crohn’s and Colitis Education Conference, “Medication Update”, September 2018, San Diego, CA.
168. Gastrointestinal Health Foundation, “IBD Alliance Program 2018”, September, 2018, Bethesda, MD.
169. Gastrointestinal Health Foundation, “IBD Alliance Program 2018”, September, 2018, Columbia, MD.
170. University of Wisconsin, “Optimizing therapy in patients with moderate to severe inflammatory bowel disease”, October, 2018, Madison, WI.
171. Gastrointestinal Health Foundation, “IBD Alliance Program 2018”, November, 2018, Bethesda, MD.
172. NorthShore University Health System, “Telemedicine for Patients with Inflammatory Bowel Disease”, December, 2018, Evanston, IL.
173. Harbor Hospital, “Recognizing and Managing Iron Deficiency Anemia in Inflammatory Bowel Disease”, January 2019, Baltimore, MD.
174. Gastrointestinal Health Foundation, “IBD Alliance Program 2018”, January, 2019, Columbia, MD.
175. 2019 Crohn’s and Colitis Congress, “Trends in IBD Care Breakout A: Creating an IBD Center with Varying Degrees of Resources: From University to Sole Practitioner”, February 2019, Las Vegas, NV.
176. 2019 Crohn’s and Colitis Congress, “Stricture Management”, February 2019, Las Vegas, NV.
177. IBD Horizon’s 2nd Annual Midwest Columbus Symposium, “Management of proctosigmoiditis beyond mesalamine”, February 2019, Columbus, OH.
178. LSU 4th Annual IBD Conference, “Where to position tofacitinib in UC and ustekinumab in CD”, March 2019, New Orleans, LA.
179. Capital Digestive Care, “IBD Roundtable”, March 2019, Bethesda, MD.
180. Walter Reed Medical Center, “IBD Roundtable”, April 2019, Bethesda, MD.
181. Akron Digestive Disease Consultants, “IBD Roundtable”, April 2019, Akron, OH.
182. Northeast Ohio Medical University 30th Anniversary of the Annual Internal Medicine Update Course, The Next 30 Years, “Inflammatory Bowel Disease and Telemedicine”, May 2019, Rootstown, OH.
183. Fifth Annual Orlando Clinical Updates in Inflammatory Bowel Disease, May 2019, “How to manage biologics in the perioperative period and management of Crohn’s disease after surgery”, Orlando, FL.
184. Fifth Annual Orlando Clinical Updates in Inflammatory Bowel Disease, May 2019, “Positioning tofacitinib in the treatment of ulcerative colitis and future therapies on the horizon”, Orlando, FL.
185. Digestive Diseases Week, “Evaluating symptoms after a switch: “nocebo” effect vs. disease relapse”, May 2019, San Diego, CA.
186. American Society of Gastrointestinal Endoscopy IBD Special Interest Group, “Stricture management, May 2019, San Diego, CA.
187. Visiting Professor Brigham and Women’s Hospital, “Telemedicine for Patients with Inflammatory Bowel Disease”, July 2019, Boston, MA.
188. Advances in Inflammatory Bowel Disease, “Mild to Moderate UC”, September 2019, Baltimore, MD.
189. Temple Health Gastroenterology Fellow Symposium, “Healing the Bowel: Is It Needed and How Do You Do It?”, September 2019, Philadelphia, PA.
190. IBD ReMEdy, “Evolving Treatment Goals and Paradigms in IBD”, November 2019, Atlanta, GA.
191. Advances in IBD, “Malignancy and Management of IBD”, December 2019, Orlando, FL.
192. Advances in IBD, “How I do it in My Practice: Therapeutic Drug Monitoring”, December 2019, Orlando, FL.
193. Advances in IBD, “Strictures: Operate, Dilate, or Medicate?”, December 2019, Orlando, FL.
194. Advances in IBD, “Hospitalized UC Cases”, December 2019, Orlando, FL.
195. Advances in IBD, “Making the Switch: The Use of Biosimilars in IBD Management”, December 2019, Orlando, FL.
196. Lehigh Valley Hospital GI Grand Rounds, “Exploring the Future of IBD Care: The Role of JAK Inhibitors”, December 2019, Allentown, PA.
197. George Washington University Medical Grand Rounds, “Exploring the Future of IBD Care: The Role of JAK Inhibitors”, December 2019, Washington, DC.
198. Georgetown Gl Grand Rounds, “Exploring the Future of IBD Care: The Role of JAK Inhibitors”, January 2020, Washington, DC.
199. IBD APP & Nurse Preceptorship, “Welcome and IBD Overview”, January 2020, Baltimore, MD.
200. IBD APP & Nurse Preceptorship, “Evolving Treatment Goals”, January 2020, Baltimore, MD.
201. IBD APP & Nurse Preceptorship, “Biologics and Emerging IBD Therapies”, January 2020, Baltimore, MD.
202. IBD APP & Nurse Preceptorship, “Putting It All Together”, January 2020, Baltimore, MD.
203. IBD APP & Nurse Preceptorship, “IBD Support Foundation Core Competencies for Advanced Practitioners”, January 2020, Baltimore, MD.
204. Crohn’s and Colitis Foundation Congress, “Inflammatory Bowel Disease and Telemedicine”, January 2020, Austin, TX.
205. Gut Club, “Therapeutic Drug Monitoring in IBD: How I do it in My Practice”, February 2020, Rochester, NY.
206. University of Rochester Division of Gastroenterology and Hepatology GI Clinical Conference, “Healing the Bowel: Is it Needed and How Do You Do it?”, February 2020, Rochester, NY.
207. Gastrointestinal Health Foundation “IBD Alliance Program 2019”, February 2020, Baltimore, MD.
208. 8th Annual UCLA-Mellinkoff Gastroenterology and Hepatology Symposium, “Therapeutic Drug Monitoring: My Approach”, Los Angeles, CA.
209. 8th Annual UCLA-Mellinkoff Gastroenterology and Hepatology Symposium, “Positioning Old and New Therapies in IBD”, Los Angeles, CA.
210. Gastrointestinal Health Foundation “IBD Alliance Program 2019”, March 2020, Baltimore, MD.
211.
Interviews
1. Telemanagement and IBD. Gastroenterology and Hepatology April 2014
2. Biologics in Ulcerative Colitis. Everyday Health March 2014
3. Telemanagement of IBD. HCPLive May 2014
4. New Drug for Crohn’s Disease Shows Early Promise. HealthDay. March 2015.
5. Telemedicine for Patients with IBD. EndoNurse May 2015.
6. Expert Answers to Questions about Crohn’s Disease. WebMd October 2015.
7. De-escalation Strategies in IBD”. Gastroenterology and Endoscopy News. January 2016.
8. J&J/Janssen’s Stelara Phase III Crohn’s data encourages EMA/FDA nods despite underwhelming efficacy-experts. Biopharma Insight. April 2016.
9. J&J/Janssen’s Stelara stirs uptake debate given wavering refractory need in Crohn’s, niche potential-experts. Biopharma Insight. April 2016.
10. Superhero Fights for IBD Awareness. Healthline News. July 2016.
Proffered Communications
1. Greenberg, R, Ioffe, O, Greenwald, B, Roth, JS, Cross, RK, Severe Squamous Dysplasia of the Rectum in a Patient with Ulcerative Colitis Treated with Mercaptopurine, 2007 Maryland ACP Mulholland-Mohler Associates meeting, Baltimore, Maryland 2007.
2. Cross, RK, Cheevers, N, Lambert, K, Steele, AG, Stozhkov, P, Finkelstein, J, Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). 6th Annual Broad Medical Research Program Meeting, Los Angeles, California, February 2008
3. Cross, RK, Cheevers, N, Lambert, K, Steele, AG, Stozhkov, P, Finkelstein, J, Home Telemanagement for Patients with Ulcerative Colitis (UC HAT). 7th Annual Broad Medical Research Program Meeting, Los Angeles, California, February 2009
4. Razeghi, S, Halvorson, C, Gaspari, A, and Cross, RK. Successful Treatment of Localized Pyoderma Faciale in a Patient with Crohn’s Disease. Poster presentation, Maryland ACP Conference, Baltimore, Maryland, May, 2012
5. Christian, K, Hagan, M, Jambaulikar, GD, Briscoe, J, Brown, S, Campbell, E, Syed, A, Gadani, A, and Cross, RK. Predictors of Readmission in Hospitalized Patients with Inflammatory Bowel Disease Treated at a Tertiary Care Hospital, American College of Physicians, Associates Day Meeting, Baltimore, Maryland, May 2015.
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- university of maryland jobs baltimore
- university of maryland nursing jobs
- university of maryland hospital jobs
- university of maryland medical system careers
- university of maryland jobs
- university of maryland college park jobs
- university of maryland baltimore jobs
- university of maryland hospital baltimore
- university of maryland baltimore careers
- university of maryland jobs openings
- university of maryland hospital careers
- university of maryland baltimore county jobs